Technical Field The present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as TRPV1 antagonist; and a pharmaceutical composition containing the same. Background Art The vanilloid receptor-1 (VR1, or transient receptor potential vanilloid-1, TRPV1) is the receptor for capsaicin (8-methyl-N-vanillyl-6-nonenamide), a pungent ingredient in hot peppers. The molecular cloning of TRPV1 was reported in 1997 (Caterina et al., 1997, Nature, 389, pp816-824), which belongs to the TRP channel family of non-selective cation channel. TRPV1 is activated or sensitized by stimuli such as capsaicin, resiniferatoxin, heat, acid, anandamide, lipid metabolites or the like ; thus it plays a crucial role as a molecular integrator of noxious stimuli in mammals (Tominaga et al., 1998, Neuron, 21 pp531-543; Hwang et al., 2000, PNAS, 97, pp6155-6160). The TRPVI is highly expressed in primary afferent sensory neurons, and also reportedly expressed in various organs and tissues such as bladder, kidney, lung, intestine, skin, central nervous system (CNS), and non-neuronal tissues (Mezey et al., 2000, PNAS, 97, pp3655-3660; Stander et al., 2004, Exp. Dermatol. 13, pp129-139; Cortright et al., 2001, BBRC, 281, pp1183-1189), and besides TRPV1 protein is upregulated in painful disease conditions. Activation of the TRPV1 by endogenous/exogenous stimuli leads to not only transmission of noxious stimuli, but also liberation of neuropeptides such as substance P, CGRP (Calcitonin Gene-Related Peptide) in the neurons, thereby causing neurogenic inflammation. TRPV1 knock-out mice show normal responses in a wide range of behavioural tests including noxious mechanical and acute thermal stimuli, but exhibit little thermal hypersensitivity in inflammation states. (Caterina et al., 2000, Science, 288, pp306-313; Davis et al., 2000, Nature, 405, pp183-187; Karai et al., 2004, J. Clin. Invest., 113, pp1344-1352). As mentioned above, the TRPV1 knock-out mice exhibit reduced responses to thermal or noxious stimuli, which has been supported by the effects of TRPV1 antagonists in various animal models of pain (Immke et al., 2006, Semin. Cell. Dev. Biol., 17(5), pp582-91; Maet al., 2007, Expert Opin. Ther. Targets, 11(3), pp307-20). The well-known TRPV1 antagonist, capsazepine, decreases hyperalgesia caused by physical stimuli in several models of inflammatory and neuropathic pain (Walker et al., 2003, JPET, 304, pp56-62; Garcia-Martinez et al., 2002, PNAS, 99, 2374-2379). In addition, treatment of the primary culture of afferent sensory neurons with the TRPV1 agonist, capsaicin etc., results in damage to nerve functions and furthermore death of nerve cells. The TRPV1 antagonist exerts defense actions against such damage to nerve functions and nerve cell death (Holzer P., 1991, Pharmacological Reviews, 43, pp143-201; Mezey et al., 2000, PNAS, 97, 3655-3660). The TRPV1 is expressed on sensory neurons distributed in all regions of the gastrointestinal tract and is highly expressed in inflammatory disorders such as irritable bowel syndrome and inflammatory bowel disease (Chan et al., 2003, Lancet, 361, pp385-391 ; Yiangou et al., 2001, Lancet, 357, pp1338-1339). In addition, activation of the TRPV1 stimulates sensory nerves, which in turn causes release of neuropeptides which are known to play a critical role in pathogenesis of gastrointestinal disorders such as gastro-esophageal reflux disease (GERD) and stomach duodenal ulcer (Holzer P., 2004, Eur. J. Pharmacol. 500, pp231-241; Geppetti et al., 2004, Br. J. Pharmacol., 141, pp 1313-1320). The TRPVI-expressing afferent nerves are abundantly distributed in airway mucosa, and bronchial hypersensitivity is very similar mechanism to hyperalgesia. Protons and lipoxygenase products, known as endogenous ligands for the TRPV1, are well known as crucial factors responsible for development of asthma and chronic obstructive pulmonary diseases (Hwang et al., 2002, Curr. Opin. Pharmacol. pp235-242; Spina et al., 2002, Curr. Opin. Pharmacol. pp264-272). Moreover, it has been reported that air-polluting substances which are a kind of asthma-causing substances, i.e., particulate matter specifically acts on the TRPV1 and such action is inhibited by capsazepine (Veronesi et al., 2001, NeuroToxicology, 22, pp795-810). Urinary bladder hypersensitiveness and urinary incontinence are caused by various central/peripheral nerve disorders or injury, and TRPV1 expressed in afferent nerves and urothelial cells play an important role in bladder inflammation. (Birder et al., 2001, PNAS, 98, pp13396-13401). Further, TRPV1 knock-out mice are anatomically normal but have higher frequency of low-amplitude, non-voiding bladder contractions and reduced reflex voiding during bladder filling as compared to wild type mice, which is thus indicating that the TRPV1 affects functions of the bladder (Birder et al., 2002, Nat. Neuroscience, 5, pp856-860). The TRPV1 is distributed in human epidermal keratinocytes as well as in primary afferent sensory nerves (Denda et al., 2001, Biochem. Biophys. Res. Commun., 285, pp 1250-1252; Inoue et ah, 2002, Biochem. Biophys. Res. Commun., 291, pp124-129), and it is men involved in transmission of various noxious stimuli and pains such as skin irritation and pruritus, thereby having close correlation with etiology of dermatological diseases and disorders, such as skin inflammation, due to neurogenic/non-neurogenic factors. This is supported by the report that the TRPV1 antagonist, capsazepine inhibits inflammatory mediators in human skin cells (Southall et al., 2003, J. Pharmacol. Exp. Ther., 304, pp217-222). Over recent years, evidence has been accumulation on other roles of TRPV1. TRPV1 might be involved in the blood flow/pressure regulation via sensory vasoactive neuropeptide release and in the regulation of plasma glucose levels or in the pathogenesis of type 1 diabetes (Inoue et al., Cir. Res., 2006, 99, ppl 19-31; Razavi et al., 2006, Cell, 127, ppl 123-35; Gram et al., 2007, Eur. J. Neurosci., 25, pp213-23). Further, it is reported that TRPV1 knock-out mice show less anxiety-related behavior than their wild type lirtermates with no differences in locomotion (Marsch et al., 2007, J. Neurosci.,27(4), pp832-9). Based on the above-mentioned information, development of various TRPV1 antagonists is under way, and some patents and patent applications relating to TRPV1 antagonists under development were published. (Szallasi et al., 2007 , Nat. Rev. Drug Discov., 6, pp357-72; Appendino et al., 2006, Progress in Medicinal Chemistry, 44, pp145-180 ; Rami et al., 2004, Drug Discovery Today: Therapeutic Strategies, 1, pp97-104 ; Correll et al., 2006, Expert Opin. Ther. Patents, 16, pp783-795 ; Kyle et al., 2006, Expert Opin. Ther. Patents, 16, pp977-996) Compounds of the present invention, are useful for prophylaxis and treatment of diseases associated with the activity of TRPV1 (Nagy et al., 2004, Eur. J. Pharmacol. 500, 351-369) including but not limited to, pain such as acute pain, chronic pain, neuropathic pain, post-operative pain, rheumatic arthritic pain, osteoarthritic pain, postherpetic neuralgia, neuralgia, headache, dental pain, pelvic pain, migraine, bone cancer pain, mastalgia and visceral pain (Petersen et al., 2000, Pain 88, pp125-133; Walker et al., 2003, J. Pharmacol. Exp. Ther., 304, pp56-62; Morgan et al.,2005, J. Orofac. Pain, 19, pp248-60 ; Dinis et al., 2005, Eur. Urol., 48, pp162-7; Akerman et al., 2004, Br. J. Pharmcol., 142, ppl354-1360; Ghilardi et al., 2005, J. Neurosci., 25, 3126-31; Gopinath et al., 2005, BMC Womens Health, 5, 2-9); nerve-related diseases such as neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, and stroke (Park et al., 1999, Arch. Pharm. Res. 22, pp432-434; Kim et al., 2005, J. Neurosci. 25(3), pp662-671); diabetic neuropathy (Kamei et al., 2001, Eur. J. Pharmacol. 422, pp83-86); fecal urgency; irritable bowel syndrome (Chan et al., 2003, Lancet, 361, pp385-391); inflammatory bowel disease (Yiangou et al., 2001, Lancet 357, pp1338-1339); gastrointestinal disorders such as gastro-esophageal reflux disease (GERD), stomach duodenal ulcer and Crohn's disease (Holzer P, 2004, Eur. J. Pharm., 500, pp231-241; Geppetti et al., 2004, Br. J. Pharmacol., 141, pp1313-1320); respiratory diseases such as asthma, chronic obstructive pulmonary disease, cough (Hwang et al., 2002, Curr. Opin. Pharmacol. pp235-242; Spina et al., 2002, Curr. Opin. Pharmacol. pp264-272; Geppetti et al., 2006, Eur. J. Pharmacol., 533, pp207-214; McLeod et al., 2006, Cough, 2, 10); urinary incontinence (Birder et al., 2002, Nat. Neuroscience 5, pp856-860); urinary bladder hypersensitiveness (Birder et al, 2001, PNAS, 98, pp13396-13401); neurotic/allergic/inflammatory skin diseases such as psoriasis, pruritus, prurigo and dermatitis (Southall et al., 2003, J. Pharmacol. Exp. Ther., 304, pp217-222); irritation of skin, eye or mucous membrane (Tominaga et al., 1998, Neuron 21 pp531-543); hyperacusis; tinnitus; vestibular hypersensitiveness (Balaban et al., 2003, Hear Res. 175, pp165-70); cardiac diseases such as myocardial ischemia (Scotland et al., 2004, Circ. Res. 95, ppl027-1034; Pan et al., 2004, Circulation 110, ppl826-1831); haemorrhagic shock (Akabori et al., 2007, Ann. Surg., 245(6), pp964-70) ; hair growth-related disorders such as hirsutism, effluvium, alopecia (Bodo et al., 2005, Am. J. Patho. 166, pp985-998; Biro et al., 2006, J. Invest. Dermatol. ppl-4) ; rhinitis (Seki et al., 2006, Rhinology, 44, ppl28-34) ; pancreatitis (Hutter et al., 2005, Pancreas, 30, pp260-5) ; cystitis (Dinis et al., 2004, J. Neurosci., 24, pp11253-63; Sculptoreanu et al., 2005, Neurosci. Lett. 381, pp42-6) ; vulvodynia (Tympanidis et al.,,2004, Eur. J. Pain, 8, pp12-33); psychiatric disorders such as anxiety or fear (Marsch et al., 2007, J. Neurosci.,27(4), pp832-9). Compounds that are related to VR1 activities are discussed e.g. in WO 02/61317, WO 02/090326, WO 02/16318, WO 02/16319, WO 03/053945, WO 03/099284, WO 03/049702, WO 03/049702, WO 03/029199, WO 03/70247, WO 04/07495, WO 04/72068, WO 04/035549. WO 04/014871, WO 04/024154, WO 04/024710, WO 04/029031, WO 04/089877, WO 04/089881, WO 04/072069, WO 04/111009, WO 05/03084, WO 05/073193, WO 05/051390, WO 05/049613, WO 05/049601, WO 05/047280, WO 05/047279, WO 05/044802, WO 05/044786, WO 06/097817, WO 06/098554, WO 06/100520, WO 06/101321, WO 06/102645, WO 06/103503, WO 06/111346, WO 06/101321, WO 06/101318, WO 06/1113769, WO 06/116563, WO 06/120481, WO 06/122250, WO 06/122799, WO 06/129164, WO 06/51378, WO 06/95263, WO 07/42906, WO 07/45462, WO 07/50732, WO 07/54474, WO 07/54480, WO 07/63925. WO 07/65663, WO 07/65888, WO 07/67619, WO 07/67710, WO 07/67711. WO 07/67756, WO 07/67757, WO07/63925, WO07/65662, WO07/65663, WO07/65888, WO07/69773, US20070149517, or US20070149513. More specificically, WO 06/101321 and WO 06/101318 relate to VR1 modulators with a biphenyl partial structure. As a result of extensive and intensive studies, the present inventors have consequently synthesized novel compounds having VR1 antagonistic activity by the replacement of one phenyl ring with a substituted heterocyclic ring. Furthermore, the present inventors have also surprisingly identified that the replacement of one phenyl ring as mentioned above provided the improvement of their physicochemical characteristics, such as metabolic stability or pharmacokinetic profiles. Therefore, it is an object of the present invention to provide novel compounds useful as a potent antagonist for a TRPV1, isomer thereof and pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising the same. Disclosure of Invention The present invention provides a novel compound of the following formula (I), an isomer, or a pharmaceutically acceptable salt thereof: (Formula Removed) wherein, (Formula Removed) X is CRu=CR12, CHRnCHR12, RIZ , Rl2 , or C=C, wherein, RM and Ru, if present, are independently hydrogen, halogen, or C1-C10 alkyi; Y and Z are independently CH, CR6, or N, such that at least one of Y and Z is N; R1 IS hydrogen, halogen, or alkyi (preferably C1-C10 alkyi); R2, RS, R4, and R$ are independently hydrogen, halogen, nitro, cyano, alkyi (preferably C1-C10 alkyi), alkoxy (preferably C1-C10 alkoxy), haloalkyl (preferably halo (Cl- C10) alkyi), alkenyl (preferably C2-C10 alkenyl), alkynyl (preferably C2-C10 alkynyl), carboxy, alkoxycarbonyl (preferably C1-C10 alkoxycarbonyl), or alkylthio (preferably C1-C10alkylthio); R6, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, alkyl (preferably C1-C10 alkyl), alkoxy (preferably C1-C10 alkoxy), alkenyl (preferably C2-C10 alkenyl), alkynyl (preferably C2-C10 alkynyl), alkylthio (preferably C1-C10 alkylthio), alkylsulfonyl (preferably C1-C10 alkylsulfonyl), alkylcarbonyl (preferably C1-C10 alkylcarbonyl), alkoxycarbonyl (preferably C1-C10 alkoxycarbonyl), alkenyloxy (preferably C2-C10 alkenyloxy), alkoxyalkoxy (preferably C1-C10 alkoxy (C1-C10) alkoxy), alkoxyalkoxyalkyl (preferably C1-C10 alkoxy (C1-C10) alkoxy (C1-C10) alkyl), piperidyl, piperazinyl, alkoxyalkylamino (preferably C1-C10 alkoxy (C1-C10) alkylamino), alkylamino (preferably C1-C10 alkylamino), dialkylamino (preferably di(Cl-C10 alkyl)amino), cycloalkyl (preferably C3-C8 cycloalkyl), cycloalkylamino (preferably C3-C8 cycloalkylamino), cycloalkoxy (preferably C3-C8 cycloalkoxy), oxacycloalkyloxy (preferably C3-C8 oxacycloalkyloxy), N-alkoxyalkyl-N-alkylamino (preferably N-(C1-C10) alkoxy (C1-C10) alkyl-N-(C1-C10) alkylamino), N-cycloalkyl-N-alkylamino (preferably N-(C3-C8) cycloalkyl-N-(Cl-C10) alkylamino), N-aryl-N-alkylamino (preferably N-aryl-N-(C1-C10) alkylamino, more preferably N-phenyl-N-(C1-C10)alkylamino), aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, heteroaryl preferably pyridinyl or thienyl, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8), cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroarylamino, or heteroaryloxy, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and - each piperazinyl, piperidyl, morpholinyl, and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxy(Cl-C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, or hydroxyl; and Rio is alkyl (preferably C1-C10 alkyl), haloalkyl (preferably halo (C1-C10) alkyl), or alkenyl (preferably C2-C10 alkenyl) The present invention provides a novel compound of the following formula (I), an isomer, or a pharmaceutically acceptable salt thereof: (Formula Removed) wherein, X is CR11=CR12, CHR11CHR11, ,or C=C, wherein, R11 and Ri2, if present, are independently hydrogen, halogen, or C1-C5 alkyl; Y and Z are independently CH, CR6, or N, such that at least one of Y and Z is N, RI is hydrogen, halogen, or C1-C5 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl- C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6, R7, R8, and R9are uidependently hydrogen, hydroxy, halogen, nitro, carboxy, Cl- ClO alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, Cl- C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, piperazinyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyloxy, N-(C1-C5) alkoxy (C1-C5) alkyl-N-(C1-C5) alkylamino, N-(C3-C8) cycloalkyl-N-(C 1-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino preferably N-phenyl-N-(Cl-C5)alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, heteroaryl preferably pyridinyl or thienyl, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8), cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroarylamino, or heteroaryloxy, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or ammo, and - each piperazinyl, piperidyl, morpholinyl, and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxy(Cl-C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, or hydroxyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl, and wherein, in one embodiment, preferably, Z is N, Y is CR6, and R7 is C3-C6 alkyl or halo(Cl-C5 alkyl), e.g. trifluoromethyl, and wherein, in another embodiment, in said compounds of formula I, preferably X is CR11=CR12 or OC, Z is N, Y is CR6, R is different from hydrogen, and R7 is halo(Cl-C5 alkyl), particularly preferably trifluoromethyl. The present invention provides a novel compound of the following formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, (Formula Removed) X is CR11=CR12, CHR11CHR12, Rl2 , Rl2 , or OC, wherein, R11 and R12, if present, are independently hydrogen, halogen, or C1-C5 alkyl; Y and Z are independently CH, CR6, or N, such that at least one of Y and Z is N; R1 is hydrogen or C1-C5 alkyl; R2, R3, R4, and RS are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl- C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, Cl-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, piperazinyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyloxy, N-(C1-C5) alkoxy (C1-C5) alkyl-N-(Cl-C5) alkylamino, N-(C3-C8) cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(C1-C5) alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8), cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, or unsubstituted or halo-substituted di(Cl-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroarylamino, or heteroaryloxy, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and - each piperazinyl, piperidyl, morpholinyl, and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, or hydroxyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl. The present invention also provides a novel compound of the following formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same; (Formula Removed) wherein, (Formula Removed) X is CR11=CR12 , CHR11CHR12 , R12 , R12 , Or OC, wherein, R11 and R12, if present, are independently hydrogen, halogen, or C1-C5 alkyl; Y and Z are independently CH, CR6, or N, such that at least one of Y and Z is N; R1 IS hydrogen or C1-C5 alkyl; R2, RS, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl-C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; RS, RT, Rg, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl-C5 alkyl, C1-C5 alkoxy, hydroxy (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, halo (C1-C5) alkyl, halo (C1-C5) alkoxy, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C2-C5 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, C1-C3 alkylpiperazinyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C7 alkylamino, di(Cl-C5 alkyl)amino, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more C1-C3 alkyl groups, pyrrolidinyl, phenyl, or morpholinyl, wherein the phenyl may be unsubstituted or substituted with one or more substituents selected from halogen, C1-C5 alkyl, and halo (C1-C5) alkyl; and Rio is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl. Another aspect of the present invention is a compound according to the above formula (I), an isomer, or a pharmaceutically acceptable salt thereof; wherein, X is CRu=CR12, wherein, Rn and R[2, are independently hydrogen, halogen, or C1-C3 alkyl; R1 is hydrogen or C1-C3 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, methyl, ethyl, ethenyl, ethynyl, trifluoromethyl, methoxy, ethoxy, or methoxycarbonyl; R6, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl-C5 alkyl, C1-C5 alkoxy, hydroxy (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, halo (C1-C5) alkyl, halo (C1-C5) alkoxy, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C2-C5 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, C1-C3 alkylpiperazinyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C7 alkylamino, di(Cl-C3 alkyl)amino, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, pyrrolidinyl, phenyl, or morpholinyl, wherein the phenyl may be unsubstituted or substituted with one or more substituents selected from halogen, Cl-C5 alkyl, and halo (C1-C5) alkyl; and R10 is C1-C3 alkyl or C2-C3 alkenyl. According to one embodiment of the present invention, in the compounds of formula I as further described herein, R6 is different from hydrogen, and R7 is halo (C1-C5 )alkyl, preferably halo (C1-C4) alkyl, more preferably halo (C1-C2) alkyl such as CF2C1 or CF2CF3, particularly preferably R7 is CF3. According to another embodiment of the present invention, in the compounds of formula (I) as further described herein, - Z is N; - Y is CR6; - X is CR11=CR12 , CHR11CHR12 , or OC; - R7 is C3-C6 alkyl or halo(Cl-C5) alkyl; and R7 is even more preferably tert-butyl, isopropyl, isobutyl, or trifluoromethyl; and R6 is not pyridynyl, pyridinyloxy, piperazinyl, a hydroxyl-substituted alkylamino, or a substituted pyrrolidine. In some embodiments R6 is also not hydrogen. In another embodiment, R6 is not hydrogen and also not phenylthio. Accordingly, one embodiment of the present invention is a compound of the formula (I), an isomer, or a pharmaceutically acceptable salt thereof: (Formula Removed) wherein, - X is CR11=CR12 or OC; wherein, Rn and Ri2, if present, are independently hydrogen, halogen, or C1-C5 alkyl; - Z is N; - Y is CR6; R1 is hydrogen, halogen, or C1-C5 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl- C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6 is hydroxy, halogen, nitro, carboxy, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, C1-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, Cl- C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyloxy, N-(C1-C5) alkoxy (C1-C5) alkyl-N-(Cl-C5) alkylamino, N-(C3-C8) cycloalkyl-N-(C1-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino preferably N-phenyl-N-(Cl-C5)alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, thienyl, heteroarylamino, aryloxy preferably phenoxy, pyrrolidinyl, or morpholinyi, provided that R6 is not a hydroxyl-substituted alkylamino; R8 and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, C1-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, piperazinyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyloxy, N-(C1-C5) alkoxy (C1-C5) alkyl-N-(C1-C5) alkylamino, N-(C3-C8) cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino preferably N-phenyl-N-(Cl-C5)alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, heteroaryl preferably pyridinyl or thienyi, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyi, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8), cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroarylamino, or heteroaryloxy, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and - each piperidyl and morpholinyl, may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxy(Cl- C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, orhydroxyl; R7ishalo(Cl-C5)alkyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl. In another embodiment, hi the compounds of formula I as described herein, X is -CH=CH-, -C(CH3)=CH-, -CH=C(CH3)-, -C(CH3)=C(CH3)-, -C(C2H5)=CH-, - CH=C(C2H3)-, -CF=CH-, -CH=CF-, or OC; R1 IS hydrogen, fluoro, methyl, or ethyl; R2, R3, R4, and R5 are independently hydrogen, fluoro, chloro, bromo, nitro, cyano, methyl, ethyl, ethenyl, ethynyl, trifluoromethyl, methoxy, ethoxy, or methoxycarbonyl; RS is hydroxy, fluoro, bromo, chloro, hydroxymethyl, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, halo (C1-C6) alkyl, halo (C1-C6) alkoxy, C2-C6 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, di(Cl-C6 alkyl)amino, C1-C6 alkylamino, C1-C3 alkoxy (C1-C5) alkylamino, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, C3-C6 cycloalkylamino which may be unsubstituted or substituted with one or more methyl groups, C3-C6 cycloalkoxy, C3-C6 oxacycloalkoxy, N-(C1-C2) alkoxy (C1-C3) alkyl-N-(Cl-C3) alkylamino, N-(C3-C6) cycloalkyl-N-(Cl-C3) alkylamino, C1-C3 alkylpiperazinyl, piperidyl, pyrrolidinyl. halophenyl, phenyl, phenoxy, phenylamino, halophenoxy, morpholinyl; C1-C2 alkoxy (C1-C3) alkyl, phenyl(Cl-C3)alkyl, phenyl(C2-C3)alkenyl, C1-C3 alkoxyalkynyl, di(Cl-C3)alkylaminoalkynyl, (Cl-C3)alkoxyphenyl, thienyl, (C3-C6) cycloalkyl (C1-C3) alkoxy, phenyl (C1-C3) alkoxy, C1-C5 alkylthio, phenyl (C1-C3) alkylamino, arylamino, N-phenyl-N-(Cl-C3) alkylamino, (Cl-C3)alkoxycarbonyl, or piperidyl; R7 is halo (C1-C5) alkyl, such as CF2C1, CF2CF3 or, particularly preferably, CF3; R8 and R7 are independently hydrogen, halogen, or trifluoromethyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl. The present invention also provides a novel compound of the following formula (II), an isomer, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, R1 is hydrogen or C1-C5 alkyl; R2, R3, R4, and RS are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl- C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl- C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl, C2-C5 alkynyl, halo (C1-C5) alkyl, halo (Cl- C5) alkoxy, hydroxy (C1-C5) alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C2-C5 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, C1-C3 alkylpiperazinyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C7 alkylamino, di(Cl-C5 alkyl)amino, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more C1-C3 alkyl groups, pyrrolidinyl, phenyl, or morpholinyl, wherein the phenyl may be unsubstituted or substituted with one or more substituents selected from halogen, C1-C5 alkyl, and halo (C1-C5) alkyl; R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl; and R11 and R12 are independently hydrogen, C1-C5 alkyl, or halogen. One preferred aspect of the present invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, R1 is hydrogen, halogen or C1-C10 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, alkyl (preferably C1-C10 alkyl), alkoxy (preferably C1-C10 alkoxy), haloalkyl (preferably halo (Cl-C10) alkyl), alkenyl (preferably C2-C10 alkenyl), alkynyl (C2-C10 alkynyl), carboxy, alkoxycarbonyl (preferably C1-C10 alkoxycarbonyl), or alkylthio (preferably C1-C10 alkylthio); R6, R7, R8, and R9 are independently hydrogen, hydroxy, halogen, nitro, carboxy, alkyl (preferably C1-C10 alkyl), alkoxy (preferably C1-C10 alkoxy), alkenyl (preferably C2-C10 alkenyl), alkynyl (preferably C2-C10 alkynyl), alkylthio (preferably C1-C10 alkylthio), alkylsulfonyl (preferably C1-C10 alkylsulfonyl), alkylcarbonyl (preferably C1-C10 alkylcarbonyl), alkoxycarbonyl (preferably C1-C10 alkoxycarbonyl), alkenyloxy (preferably C2-C10 alkenyloxy), alkoxyalkoxy (preferably C1-C5 alkoxy (C1-C10) alkoxy), alkoxyalkoxyalkyl (preferably C1-C5 alkoxy (C1-C10) alkoxy (Cl-C10) alkyl), piperidyl, piperazinyl, alkoxyalkylamino (preferably C1-C10 alkoxy (Cl-C10) alkylamino), alkylamino (preferably C1-C10 alkylamino), dialkylamino (preferably di(Cl-C10 alkyl)amino), cycloalkyl (preferably C3-C8 cycloalkyl), cycloalkylamino (preferably C3-C8 cycloalkylamino), cycloalkoxy (preferably C3-C8 cycloalkoxy), oxacycloalkyloxy (preferably C3-C8 oxacycloalkyl-oxy), N-alkoxyalkyl-N-alkylamino (preferably N-(Cl-C10)alkoxy (C1-C10) alkyl-N-(C1-C10) alkylamino), N-cycloalkyl-N-alkylamino (preferably N-(C3-C8)cycloalkyl-N-(Cl-C10) alkylamino), N-aryl-N-alkylamino (preferably N-aryl-N-(Cl-C5) alkylamino, more preferably N-phenyl-N-(Cl-C5)alkylamino), aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, heteroaryl preferably pyridinyl or thienyl, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8) cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroaryloxy, or heteroarylamino, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, each cycloalkyl, also as a part of a group such as hi cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and - each piperazinyl, piperidyl, morpholinyl and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxy(Cl-C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, or hydroxyl; R10 is alkyl (preferably C1-C10 alkyl), haloalkyl (preferably halo (C1-C10) alkyl), or alkenyl (preferably C2-C10 alkenyl); and R11 AND R12 are independently hydrogen, C1-C5 alkyl, or halogen. A compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, R1 IS hydrogen, halogen or C1-C5 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl-C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6, R7, R8, and Rgare independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, Cl-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, piperazinyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyl-oxy, N-(Cl-C5)alkoxy (C1-C5) alkyl-N-(Cl-C5) alkylamino, N-(C3-C8)cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino, preferably N-phenyl-N-(Cl-C5)alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, heteroaryl preferably pyridinyl or thienyl, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyioxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8) cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroaryloxy, or heteroarylamino, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxyiftethyl, hydroxy, methoxy, or amino, and - each piperazinyl, piperidyl, morpholinyl and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxy(Cl-C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, or hydroxyl; R10 IS C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl; and R11 AND R12 are independently hydrogen, C1-C5 alkyl, or halogen, wherein in one embodiment R6 is preferably different from hydrogen, and R7 is halo (C1-C5) alkyl. One preferred aspect of the present invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, R1 IS hydrogen or C1-C5 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl-C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, Cl-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, piperazinyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyl-oxy, N-(Cl-C5)alkoxy (C1-C5) alkyl-N-(C1-C5) alkylamino, N-(C3-C8)cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, heteroarylamino, aryloxy preferably phenoxy, heteroaryloxy preferably pyridinyloxy, pyrrolidinyl, or morpholinyl, wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8) cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy or heteroaryloxy, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, or halo (C1-C5) alkyl, - each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and each piperazinyl, piperidyl, morpholinyl and pyrrolidinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, or hydroxyl; R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl; and RH and RIZ are independently hydrogen, C1-C5 alkyl, or halogen. One preferred aspect of the present invention is a compound of the formula (I) or (III), an isomer, or a pharmaceutically acceptable salt thereof; (Formula Removed) wherein, R1 IS hydrogen or C1-C5 alkyl; R2, R3, R4, and R5 are independently hydrogen, halogen, nitro, cyano, C1-C5 alkyl, Cl- C5 alkoxy, halo (C1-C5) alkyl, C2-C5 alkenyl, C2-C5 alkynyl, carboxy, C1-C5 alkoxycarbonyl, or C1-C5 alkylthio; R6, R7, R8, and R9are independently hydrogen, hydroxy, halogen, nitro, carboxy, Cl- C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl, C2-C5 alkynyl, halo (C1-C5) alkyl, halo (Cl- C5) alkoxy, hydroxy (C1-C5) alkyl, C1-C5 alkylthio, C1-C5 alkylsulfonyl, C1-C5 alkylcarbonyl, C1-C5 alkoxycarbonyl, C2-C5 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, C1-C3 alkylpiperazinyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C7 alkylamino, di(Cl-C5 alkyl)amino, C3-C6 cycloalkyl which may be unsubstituted or. substituted with one or more C1-C3 alkyl groups, pyrrolidinyl, phenyl, or morpholinyl, wherein the phenyl may be unsubstituted or substituted with one or more substituents selected from halogen, C1-C5 alkyl, and halo (C1-C5) alkyl; R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl; and R11 and R12 are independently hydrogen, C1-C5 alkyl, or halogen. One preferred aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a phannaceutically acceptable salt thereof as defined further herein, wherein X is CR11=CR12 or C≡C, particularly preferably CR11=CR12, wherein R11 AND R12 are preferably hydrogen, halogen or C1-C3 alkyl, and even more preferably hydrogen or methyl. Accordingly, one preferred aspect of the present invention is a compound of the formula (I), (II), or (HI), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein X is selected from among -CH=CH-, -C(CH3)=CH-, -CH=C(CH3)-, -C(CH3)=C(CH3)-, -C(C2H5)=CH-, -CH=C(C2H5)-, -CF=CH-, -CH=CF-, or OC, even more preferably -CH=CH-, -C(CH3)=CH-, or -CH=C(CH3)-, and particularly preferably -CH=CH-. One aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R7 is a C3-C6 cycloalkyl group which may be unsubstituted or substituted with one or more methyl groups, or a C1-C5 alkyl group that is optionally halogenated with one or more radicals selected from chloro, bromo, or, preferably, fluoro. Examples are methylcyclopropyl, CF3, isopropyl, t-butyl and isobutyl. In one preferred embodiment of the present invention, in the compounds of formula (III) as further described herein, R7 is C3-C6 alkyl or halo(Cl-C5 alkyl), and R7 is even more preferably tert-butyl, isopropyl, isobutyl, or trifluoromethyl. In one preferred embodiment of the present invention, in the compounds of formula (III) as further described herein, R7 is halo (C1-C5) alkyl, or halo(Cl-C4) alkyl, such as CF2C1, CF2CF3 or, particularly preferably, CF3. In another embodiment of the present invention, in the compounds of formula (HI), Rg is not pyridinyloxy, phenylthio, or a substituted pyrrolidine. In another preferred aspect of the present disclosure, R6 is different from hydrogen. In another embodiment, in the compounds of formula (III) as further described herein - R7 is C3-C6 alkyl or halo(Cl-C5 alkyl), and R7 is even more preferably tert-butyl, isopropyl, isobutyl, or trifluoromethyl; and - R6 is not pyridynyl, pyridinyloxy, piperazinyl, a hydroxyl-substituted alkylamino, or a substituted pyrrolidine. In some embodiments R6 is also not hydrogen and/or phenylthio. Another aspect of the present invention is a compound of the formula (I) or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R6 is selected from hydrogen, bromo, chloro, n-butyl, methoxy, isobutyloxy, sec-butyloxy, methoxyethoxy, diethylamino, N-pyrrolidinyl, N-piperidyl, N- morpholinyl, cyclopentylamino, n-butylamino, phenoxy, n-butyloxy, and methoxyethy lamino. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R3 is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R10 IS methyl. Another aspect of the present invention is a compound of the formula (I), (II), or (HI), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R11 and R12, if present, are both hydrogen. In another embodiment, one of R11 and R12 is hydrogen and the other one is selected from methyl, ethyl and propyl. In one embodiment, R11 may be hydrogen, and R12 may be hydrogen, methyl, ethyl or propyl, preferably hydrogen. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R4 is hydrogen, fluoro, chloro, bromo, methyl, ethyl, cyano, or trifluoromethyl. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R1 and R2 are both hydrogen. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein RI, R2, and R11 and R12, if present, are all hydrogen. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein RI, R2, and R11 and R12, if present, are all hydrogen, R10 IS methyl, and RS is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R11 and R12, if present, are both hydrogen, R10 IS methyl or ethyl, R3 is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano, and R4 is selected from hydrogen, fluoro, chloro, bromo, methyl, cyano, or trifluoromethyl. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R11 AND R12, if present, are both hydrogen, R10 IS methyl or ethyl, R3 is selected from hydrogen, fluoro, brotno, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano, and R7 is cyclopropylmethyl or a C1-C5 alkyl that is optionally halogenated with one or more radicals selected from chloro, bromo, or, preferably, fluoro. Another aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof as defined further above, wherein R11 and R12, if present, are both hydrogen, R10 IS methyl or ethyl, R2, R5 and R8 are hydrogen, R3 is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano, and R7 is a C1-C5 alkyl that is optionally halogenated with one or more radicals selected from chloro, bromo, or, preferably, fluoro. One preferred aspect of the present invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen, methyl, or ethyl; R2, R3, R4, and R5 are independently hydrogen, fluoro, chloro, bromo, nitro, cyano, methyl, ethyl, ethenyl, ethynyl, trifluoromethyl, methoxy, ethoxy, or methoxycarbonyl; R6, if present, is hydrogen, hydroxy, fluoro, bromo, chloro, hydroxymethyl, C1-C5 alkyl, C1-C5 alkoxy, C2-C5 alkenyl, C2-C5 alkynyl, halo (C1-C5) alkyl, halo (C1-C5) alkoxy, C2-C5 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, di(Cl-C3 alkyl)amino, C1-C3 alkylpiperazinyl, piperidyl, pyrrolidinyl, halophenyl, phenyl, or morpholinyl, wherein R6 is preferably different from hydrogen; R7 is C1-C5 alkyl, halo (C1-C4) alkyl, halogen, piperidyl, morpholinyl, pyrrolidinyl, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, C2-C5 alkenyl, wherein R7 is preferably halo (C1-C4) alkyl; R8 and R9 are independently hydrogen, halogen, or trifluoromethyl; R10 IS C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl; and R11 AND R12, if present, are independently hydrogen, or methyl. Another preferred embodiment of the invention is a compound of the formula (I), (II), or (III), an isomer. or a pharmaceutically acceptable salt thereof; wherein, R1, R2, and R5 are hydrogen; R3 is hydrogen, fluoro, chloro, cyano, methyl, ethenyl, ethynyl, or trifluoromethyl; R4 is hydrogen, fluoro, chloro, cyano, methyl, ethyl, or trifluoromethyl; R6, if present, is hydrogen, hydroxy, fluoro, bromo, chloro, methyl, hydroxymethyl, methoxy, trifluoromethyl, diethylamino, piperidyl, pyrrolidinyl, trifluorophenyl, phenyl, or morpholinyl, wherein R6 is preferably different from hydrogen; R7 is methyl, isopropyl, t-butyl, trifluoromethyl, chloro, bromo, cyclopropyl, methylcyclopropyl, piperidyl, pyrrolidinyl, or morpholinyl, and R7 is preferably trifluoromethyl; R8 is hydrogen; R11, and R12, if present, are hydrogen; R9 is hydrogen or trifluoromethyl; and R10 IS methyl. Another preferred embodiment of the invention is a compound of the formula (I), (II), or (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R3 is hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, ethenyl, ethynyl, or trifluoromethyl; R4 and R5 are independently hydrogen, fluoro, chloro, cyano, methyl, ethyl, or trifluoromethyl; R6, if present, is hydrogen, fluoro, chloro, bromo, methyl, methoxy, piperidyl, or morpholinyl; R7 is isopropyl, t-butyl, or, preferably, trifluoromethyl; R8 is hydrogen; R11 and R12, if present, are hydrogen; R9 is hydrogen or trifluoromethyl; and R10 IS methyl. Another preferred embodiment of the invention is a compound of the formula (I) or (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, X is -CH=CH-, -C(CH3)=CH-, -CH=C(CH3)-, -C(CH3)=C(CH3)-, -C(C2H5)=CH-, -CH=C(C2H5)-, -CF=CH-, -CH=CF-, or C=C; R1 IS hydrogen, fluoro, methyl, or ethyl; R2, R3, R4, and R5 are independently hydrogen, fluoro, chloro, bromo, nitro, cyano, methyl, ethyl, ethenyl, ethynyl, trifluoromethyl, methoxy, ethoxy, or methoxycarbonyl; R6 is hydrogen, hydroxy, fluoro, bromo, chloro, hydroxymethyl, C1-C6 alkyl, C1-C6 aikoxy, C2-C6 alkenyl, C2-C6 alkynyl, halo (C1-C6) alkyl, halo (C1-C6) alkoxy, C2- C6 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, di(Cl-C6 alkyl)amino, C1-C6 alkylamino, C1-C3 alkoxy (C1-C5) alkylamino, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, C3-C6 cycloalkylamino which may be unsubstituted or substituted with one or more methyl groups, C3-C6 cycloalkoxy, C3-C6 oxacycloalkoxy, N-(C1-C2) alkoxy (C1-C3) alkyl-N-(Cl-C3) alkylamino, N-(C3-C6) cycloalkyl-N-(Cl-C3) alkylamino, C1-C3 alkylpiperazinyl, piperidyl, pyrrolidinyl, halophenyl, phenyl, phenoxy, pyridinyloxy, phenylamino, halophenoxy, or morpholinyl; R7 is C1-C5 alkyl, halo (C1-C4) alkyl, halogen, piperidyl, morpholinyl, pyrrolidinyl, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, C2-C5 alkenyl; R8 and R9 are independently hydrogen, halogen, or trifluoromethyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl, or C2-C5 alkenyl. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1, R2, and R5 are hydrogen; R3 is hydrogen, fluoro, chloro, cyano, methyl, ethenyl, ethynyl, or trifluoromethyl; R4 is hydrogen, fluoro, chloro, cyano, methyl, ethyl, or trifluoromethyl; R6 is hydrogen, hydroxy, fluoro, bromo, chloro, methyl, propyl, butyl, pentyl, hydroxymethyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, methoxymethoxy, methoxyethoxy, methoxypropoxy, trifluoromethyl, diethylamino, methoxymethylamino, methoxyethylamino, methoxypropylamino, cyclobutyiamino, cyclopentylamino, cyclohexylamino, ethylamino, propylamino, butylamino, penrylamino, N,N-dimethylamino, N-methyl-N-ethylamino N,N-diethylamino, N- methyl-N-propylamino, N-ethyl-N-propylamino, N,N-dipropylamino, N-methyl-N- butylamino, N-ethyl-N-butylamino, N-methyl-N-methoxymethylamino, N-methyl- N-methoxyethylamino, N-methyl-N-methoxypropylamino, N-methyl-N- cyclobutylamino, N-methyl-N-cyclopentylamino, N-methyl-N-cyclohexylamino, phenoxy, halophenoxy, piperidyl, pyrrolidinyl, trifluorophenyl, phenyl, or morpholinyl, wherein R6 is preferably different from hydrogen; R7 is methyl, isopropyl, t-butyl, trifluoromethyl, chloro, bromo, cyclopropyl, methylcyclopropyl, piperidyl, pyrrolidinyl, or morpholinyl, and is preferably trifluoromethyl; R8 is hydrogen; R11 AND R12 are hydrogen; R9 is hydrogen or trifluoromethyl; and R10 IS methyl. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R3 is hydrogen, fluoro. chloro, bromo, cyano, methyl, ethyl, ethenyl, ethynyl, or trifluoromethyl; R4 and R5 are independently hydrogen, fluoro, chloro, cyano, methyl, ethyl, or trifluoromethyl; R6 is hydrogen, fluoro, chloro, bromo, methyl, n-butyl, methoxy, n-butyloxy, isobutyloxy, sec-butyloxy, methoxyethoxy, methoxyethylamino, diethylamino, n- butylamino, cyclopentylamino, phenoxy, N-pyrrolidinyl, N-piperidyl, or N- morpholinyl, wherein in one aspect R6 is different from hydrogen; R7 is isopropyl, t-butyl, or, preferably, trifluoromethyl; R8 is hydrogen; R11 and R12 are hydrogen; R9 is hydrogen or trifluoromethyl; and R10 IS methyl. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R3 is hydrogen, ethenyl, or ethynyl; R4 is hydrogen or fluoro; R5 is hydrogen; R6, is hydrogen, hydroxy, fluoro, bromo, chloro, methyl, propyl, butyl, pentyl, hydroxymethyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, methoxymethoxy, methoxyethoxy, methoxypropoxy, ethoxyethoxy, trifluoromethyl, N,N-dimethylamino, N-methyl-N-ethylamino N,N-diethylamino, N-methyl-N-propylamino, N-ethyl-N- propylamino, N,N-dipropylamino, N-methyl-N-butylamino, N-ethyl-N-butylamino, methoxymethylammo, methoxyethylamino, methoxypropylamino, N-meihyl-N- methoxymethylamino, N-methyl-N-methoxyethylamino, N-methyl-N- methoxypropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, N- methyl-N-cyciobutylamino, N-methyl-N-cyclopentylamino, N-methyl-N- cyclohexylamino, ethylamino, propylamino, butylamino, pentylamino, phenoxy, halophenoxy, N-piperidyl, N-pyrrolidinyl, trifluorophenyl, phenyl, or N-morpholinyl wherein R6 in one aspect is different from hydrogen; R7 is isopropyl, t-butyl, or, preferably, trifluoromethyl; R8 is hydrogen; R9 is hydrogen or trifluoromethyl; R10 IS methyl; and R11 AND R12 are hydrogen. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen; R2 is hydrogen; R3 is hydrogen, ethenyl, or ethynyl; R4 is hydrogen or fluoro; R5 is hydrogen; R6 is hydrogen, bromo, chloro, n-butyl, methoxy, isobutyloxy, sec-butyloxy, methoxyethoxy, diethylamino, N-pyrrolidinyl, N-piperidyl, N-morpholinyl, cyclopentylamino, n-butylamino, phenoxy, n-butyloxy, methoxyethylamino, wherein R6 in one aspect is different from hydrogen; R7 is isopropyl, t-butyl, or, preferably, trifluoromethyl; R8 is hydrogen; R9 is hydrogen or trifluoromethyl; R10 IS methyl; and R11 and R12 are hydrogen. Another aspect of the present invention is a compound of the formula (III) as further described herein, an isomer, or a pharmaceutically acceptable salt thereof, wherein, R1 IS hydrogen or methyl, wherein, if R1 IS methyl, then the compound may be a pure enantiomer or may be a mixture of the (R) and (S)-enantiomer; and then, the C-atom to which R1 IS attached is preferably in the (Reconfiguration; one of R2 and R5 is hydrogen, and the other one is hydrogen, methyl, or halogen, preferably fluoro; R3 is selected from hydrogen, fluoro, bromo, chloro, methyl, ethyl, trifluoromethyl, ethenyl, ethynyl, and cyano, preferably hydrogen, fluoro, chloro, methyl, ethyl, ethenyl, ethynyl, and cyano; R4 is hydrogen, fluoro, chloro, cyano, methyl, or ethyl; R6 is as further described in various embodiments thoroughout this application; R7 is a C1-C5 alkyl, or more preferably a C1-C4 alkyl or a C1-C3 alkyl, that is halogenated with one or more radicals selected from chloro, bromo, or, preferably, fluoro, wherein R7 is particularly preferably CF3; one of R and R9 is hydrogen, and the other one is halogen, CF3, or, preferably, hydrogen; R10 IS methyl, ethyl, or vinyl, and is preferably methyl, R11 is hydrogen; R12 is hydrogen, methyl, ethyl or propyl, and is preferably hydrogen. Another aspect of the present disclosure are compounds of the formula (III) as further described herein, an isomer, or a pharmaceutically acceptable salt thereof wherein, R6 is halogen, nitro, carboxy, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, C1-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, Cl-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (C1-C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyl-oxy, N-(Cl-C5)alkoxy (C1-C5) alkyl-N-(Cl-C5) alkylamino, N-(C3-C8)cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino, preferably N-phenyl-N-(Cl-C5)alkylamino, aryl preferably phenyl, arylamino preferably phenylamino, arylthio preferably phenylthio, thienyl, heteroarylamino, aryloxy preferably phenoxy, pyrrolidinyl, or morpholinyl, provided that R6 is not a hydroxyl-substituted alkylamino, wherein preferably, R6 is chloro, bromo, methyl, ethyl, propyl, butyl, pentyl, trifluoromethyl, ethoxymethyl, methoxypropyl, phenylethyl, phenylethenyl, ethynyl, methoxypropynyl, diethylaminopropynyl, phenyl, halophenyl, methoxyphenyl, thienyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, trifluoroethoxy, cyclopentoxy, cyclopropylmethoxy, methoxyethoxy, tetrahydropyranyloxy, phenoxy, halophenoxy, benzyloxy, ethylthio, propylthio, butylthio, pentylthio, methylamino, ethylamino, propylamino, butylamino, pentylamino, methoxyethylamino, ethoxyethylamino, methoxypropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, benzylamino, phenylamino, N,N-dimethylamino, N-methyl-N-propylamino, N-ethyl-N-propylamino, N,N- dipropylamino, N-methyl-N-butylamino, N-ethyl-N-butylamino, N-ethyl-N- phenylamino, N-methyl-N-phenylamino. N-pyrrolidinyl, N-piperidyl, ethoxycarbonyl N-piperidyl, or N-morpholinyl, wherein preferably, R6, is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, ethoxymethyl, 2-phenylethyl, phenylethenyl, phenyl, fluorophenyl, thienyl, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, 3-metylbutoxy, 2,2,2-trifluoroethoxy, cyclopentoxy, cyclopropylmethoxy, phenoxy, ethylthio, propylthio, isopropylthio, methylamino, ethylamino, n-propylamino isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxymethylamino, methoxyethylamino, ethoxyethylamino, cyclopentylamino, benzylamino, phenylamino, N-methyl-N-phenylamino, N-methyl-N-propylamino, N-pyrrolidinyl, N-piperidyl, or ethoxycarbonyl N-piperidy, wherein more preferably, R6 is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec- butylamino, methoxyethylamino, ethoxyethylamino, benzylamino, or N-methyl-N- phenylamino, wherein more preferably, R6 is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3- methylbutyl, n-pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, ethylamino, n- propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxyethylamino, benzylamino, or N-methyl-N-phenylamino, wherein even more preferably, R6 is C2-C5 alkyl, C1-C4 alkylamino, or methoxyethylamino, wherein particularly preferably, R is C3-C5 alkyl, or C2-C4 alkylamino; wherein particularly preferably, R is C2-C4 alkyl, or C1-C3 alkylamino; wherein particularly preferably, R6 is linear or branched C3 alkyl, linear C4 alkyl, or linear (C2-C3) alkylamino. Preferred examples of compounds according to the invention are selected from the group consisting of; 3-(2-Diethylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, 3-(6-tert-Butyl-pyridin-3-yl)-N-(3,5-difluoro-4-methanesulfonylamino-benzyl)-acrylamide, 3 -(2-Chloro-6-trifluoromethyl-pyridin-3 -y l)-N-(3 -ethyny 1- 5 -fluoro-4-methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(6-methoxy-4-trifluoromethyl-pyridin-3 -yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-methoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy-ethylamino)-6- trifluoromethyl-pyridin-3-yl]-acrylainide, 3 -(2-Diethylamino-6-trifluoromethyl-pyridin-3 -y l)-N-(3 -fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(6-tert-Butyl-2holin-4-yl-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino- benzyl)-acrylamide, 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-raethanesulfonylamino-benzyl)-3-(6'-trifluoromethyl-3,4,5,6- tetrahydro-2H-[l,2']bipyridinyl-3'-yl)-acrylamide, 3 -(2-Bromo-6-tert-butyl-pyridin-3 -yl)-N-(3 -fluoro-4-methanesulfony lamino-benzy 1)- acrylamide, 3-(2-Bromo-6-tert-butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesuIfonylamino- benzyl)-acrylamide, and N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-(6'-trifluoromethyl-3,4,5,6- tetrahydro-2H-[l,2']bipyridinyl-3'-yl)-acrylamide. Particularly preferred compounds according to the present invention are 3-(2-Diethylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-methoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy-ethylamino)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3 -(2-Diethylamino-6-trifluoromcthyl-pyridin-3 -yl)-N-(3 -fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(64ert-Butyl-2-chloro-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino- benzyl)-acrylamide, 3-(6-tert-Butyl-2-morpholin-4-yl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-pyrrolidin-l-yl-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, 3-(2-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino- benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy- ethy lamino)-6-trifluoromethy l-pyridin-3 -yl] -acrylamide, 3-(2-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3 -(2-Butylamino-6-trifluoromethyl-pyridin-3 -yl)-N-(3 -ethyny 1-5 -fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-Cyclopentylamino-6-tri£luoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy-ethoxy)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Butyl-5-chloro-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-metiianesulfonylamino-benzyl)-3-(2-phenoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Isopropyloxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isobutoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-[2-(tetrahydro-furan-3-yloxy)-6-trifluoromethyl-pyridin-3-yl]-N-(3-ethynyl-5-fluoro- 4-methanesulfonylamino-benzyl)-acrylamide, and N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(4-fluoro-phenoxy)-6- trifluoromethyl-pyridin-3-yl]-acrylamide. Particularly preferred compounds according to the present invention are 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, 3-(6-tert-Butyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-vinyl-benzyl)-acrylamide, N-(4-Methanesulfonylamino-3-vinyl-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3 -yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(6-tert-Butyl-2-methoxy-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino- benzyl)-acrylamide, 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-5-vinyl-benzyl)- acrylamide, 3-(6-tert-Butyl-2-methoxy-pyridin-3-yl)-N-{3-cthynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino- benzyl)-acrylamide, 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(6'-trifluoromethyl-3,4,5,6- tetrahydro-2H-[l,2']bipyridinyl-3'-yl)-acrylamide, 3-(2-Bromo-6-tert-butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-benzyl)- acrylamide, and 3-(2-Bromo-6-tert-butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino- benzyl)-acrylamide. Another preferred embodiment of the invention is a compound of the formula (I) or (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, X is -CH=CH-, -C(CH3)=CH-, -CH=C(CH3)-, -C(CH3)=C(CH3)-, -C(C2H5)=CH-, -CH=C(C2H5)-, -CF=CH-, -CH=CF-, or C=C; R1 IS hydrogen, fluoro, methyl, or ethyl; R2, R3, R4, and R5 are independently hydrogen, fluoro, chloro, bromo, nitro, cyano, methyl, ethyl, ethenyl, ethynyl, trifluoromethyl, methoxy, ethoxy, or methoxycarbonyl; R6 is C1-C2 alkoxy (C1-C3) alkyl, phenyl(Cl-C3)alkyl, phenyl(C2-C3)alkenyl, C1-C3 alkoxyalkynyl, di(Cl-C3)alkylaminoalkynyl, (Cl-C3)alkoxyphenyl, thienyl, pyridinyl, halopyridinyl, (C3-C6) cycloalkyl (C1-C3) alkoxy, phenyl (C1-C3) alkoxy, C1-C5 alkylthio, phenylthio, phenyl (C1-C3) alkylamino, arylamino, N-phenyl-N-(Cl-C3) alkylamino, hydroxy(Cl-C3)alkyl N-pyrrolidinyl, C1-C2 alkoxy N-pyrrolidinyl, (Cl- C3)alkoxycarbonyl piperidyl, piperazinyl, or C1-C3 alkylpiperazinyl, wherein Re in one embodiment is different from hydrogen; R7 is C1-C5 alkyl, halo (C1-C4) alkyl, halogen, piperidyl, morpholinyl, pyrrolidinyl, C3-C6 cycloalkyl which may be unsubstituted or substituted with one or more methyl groups, C2-C5 alkenyl, wherein R7 preferably is halo (C1-C4) alkyl; R8 and R9 are independently hydrogen, halogen, or trifluoromethyl; and R10 is C1-C5 alkyl, halo (C1-C5) alkyl. or C2-C5 alkenyl. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R1 IS hydrogen; R3 is hydrogen, fluoro, methyl, ethyl, cyano, ethenyl, ethynyl, or trifluoromethyl; R is hydrogen, fluoro, chloro, or methyl; R5 is hydrogen; R6 is fluoro, chloro, bromo, methyl, ethyl, propyl, butyl, pentyl, trifluoromethyl, ethoxymethyl, methoxypropyl, phenylethyl, phenylethenyl, ethynyl, methoxypropynyl, diethylaminopropynyl, phenyl, halophenyl, methoxyphenyl, thienyl, pyridinyl, halopyridinyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, trifluoroethoxy, cyclopentoxy, cyclopropylmethoxy, methoxyethoxy, tetrahydropyranyloxy, phenoxy, halophenoxy, benzyloxy, pyridinyloxy, ethylthio, propylthio, butylthio, pentylthio, phenylthio, ethylamino, propylamino, butylamino, pentylamino, methoxyethylamino, ethoxyethylamino, methoxypropylamino, cyclobutylamino, cyclopentylamino, cyclohexylamino, benzylamino, phenylamino, N,N-dimethylamino, N-methyl-N-propylamino, N-ethyl-N-propylamino, N,N-dipropylamino, N-methyl-N-butylamino, N-ethyl-N-butylamino, N-ethyl-N-phenylamino, N-methyl-N-phenylamino, N-pyrrolidinyl, methoxy N-pyrrolidinyl, hydroxymethyl N-pyrrolidinyl, N-piperidyl, ethoxycarbonyl N-piperidyl, piperazinyl, or N-morpholinyl; R7 is isopropyl, t-butyl, or trifluoromethyl; R8 is hydrogen; R9 is hydrogen or trifluoromethyl; R10 IS methyl; and R11 AND R12 are hydrogen. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R3 is hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, ethenyl, ethynyl, or trifluoromethyl; R4 and R6 are independently hydrogen, fluoro, chloro, cyano, methyl, or ethyl; R6 is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n- pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxyethylamino, ethoxyethylamino, benzylamino, phenylamino, N-ethyl-N-phenylamino, or N-methyl- N-phenylamino; R7 is isopropyl, t-butyl, or trifluoromethyl; R8 is hydrogen or chloro; R9 is hydrogen or trifluoromethyl, R10 IS methyl; and R11 and R12 are hydrogen. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R4 is hydrogen, fluoro, chloro, or methyl; R3 is hydrogen, fluoro, methyl, cyano, ethenyl, ethynyl, or trifluoromethyl; R5 is hydrogen; R6 is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, ethoxymethyl, 2-phenylethyl, phenylethenyl, phenyl, fluorophenyl, thienyl, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, 3- metylbutoxy, 2,2,2-trifluoroethoxy, cyclopentoxy, cyclopropylmethoxy, phenoxy, ethylthio, propylthio, isopropylthio, phenylthio, ethylamino, n-propylamino isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxymethylamino, methoxyethylamino, ethoxyethylamino, cyclopentylamino, benzylamino, phenylamino, N-ethyl-N-phenylamino, N-methyl-N-phenylamino, N-methyl-N-propylamino, N- pyrrolidinyl, methoxy N-pyrrolidinyl, N-piperidyl, or ethoxycarbonyl N-piperidyl; R7 is isopropyl, t-butyl, or trifluoromethyl; R8 is hydrogen or chloro; R9 is hydrogen or trifluoromethyl; R10 IS methyl; and R11 and R12 are hydrogen. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R1 IS hydrogen; R3 is hydrogen, fluoro, methyl, cyano, ethenyl, or ethynyl; R4 is hydrogen, fluoro, or methyl; R5 is hydrogen; R6 is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxyethylamino, ethoxyethylamino, benzylamino, N-ethyl-N-phenylamino, or N-methyl-N- phenylamino; R7 is isopropyl, t-butyl, or trifluoromethyl; R8 and R9 are hydrogen; R10 IS methyl; and R11 AND R12 are hydrogen. Another preferred embodiment of the invention is a compound of the formula (III), an isomer, or a pharmaceutically acceptable salt thereof; wherein, R1 IS hydrogen or methyl; R1 IS hydrogen; when R1 IS fluoro. R3 is hydrogen, fluoro, methyl, or ethynyl, or when R4 is hydrogen, R3 is methyl; R5 is hydrogen; R6 is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxyethylamino, ethoxyethylamino, benzylamino, N-ethyl-N-phenylamino, or N-methyl-N-phenylamino; R7 is isopropyl, t-butyl, or trifluoromethyl; R8 and R9 are hydrogen; R10 IS methyl; and R11 AND R12 are hydrogen. In a preferred aspect of the present invention, in the compounds of formula III, as described herein, R7 is a CF3 group. Another embodiment of the present disclosure are compounds having formula III, as described herein, wherein R7 is CF2C1 or CF2CF3 Preferred examples of compounds according to the invention are selected from the group consisting of; N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2,2,2-trifluoro-ethoxy)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(3-methoxy-pyrrolidin-l-yl)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Butylammo-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylammo-benzyl)-acrylamide, 3-(2-Cyclopentylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-[2-(3-methoxy-pyrrolidin-l-yl)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Cyclopropylmethoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, N-(3-Cyano-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-pyrrolidin-l-yl-6-trifiuoromethyl-pvridin-3 -yl)-acrylamide, 3-(2-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-cyano-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-sec-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-cyano-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-phenyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Cyano-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-phenylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methansulfonylamino-benzyl)-3-[2-(3-ethoxycarbony- piperid-l-yl)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Cyano-5-fluoro-4-methansulfonylamino-benzyl)-3-[2-(3-ethoxycarbony-piperid- l-yl)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Cyano-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(3-methyl-butoxy)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3 -Ethynyl-5 -fluoro-4-methanesulfonylamino-benzyl)-3 -(2-thien-3 -yl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(3-fluoro-phenyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3-Cyano-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro~4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-cyano-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Fluoro-4-methanesuIfonylamino-benzyl)-3-(2-phenylamino-6-trifluoromethyl- pyridin-3-yl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-5-methyl-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-vinyl-benzyl)-3-(2-phenoxy-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-phenylthio-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-bcnzyl)-3-(2-phenethyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-phenethyl-6- trifluoromcthyl-pyridin-3-yl)-acrylamide, 3-(2-Butyl-6-toifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylainino- benzyl)-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-(2-isobutyl-6-trifluoromethyl-pyridin- 3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-medianesulfonylamino-phenyl)-ethyl]-3-(2-phenylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Ethyl-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- raethanesulfonylamino-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methyl-butyl)-6- trifluoroinethyl-pyridin-3-yl]-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methyl-butyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfotiylamino-benzyl)-3-(2-styryl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-[2-(methyl-propyl-amino)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(methyl-propyl-amino)- 6-trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-sec-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, N-(3-Cyano-5-fluoro-4-methancsulfonylamino-benzyl)-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-[2-(methyl-phenyl- amino)-6-trifluoromethyl-pyridin-3-yl]-acrylamide. N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(methyl-phenyl-amino)- 6-trifluoromethyl-pyridin-3 -yl] -acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-[2-(methyl-phenyl-amino)-6- trifluoromethyl-pyridin-3 -y I] -acrylamide, (R)-3-(2-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, 3 -(2-Butoxy-6-trifluoromethy l-pyridin-3 -yl)-N-(4-methanesulfonylamino-3 -methy 1- benzyl)-acrylamide, 3-(2-Ethylthio-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-phenethyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-phenethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Isobutyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- benzyl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylthio-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3 -Fluoro-4-methanesulfonylamino-5 -methy l-benzyl)-3 - [2-(3 -fluoro-phenyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-[2-(3-fluoro-phenyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3-[2-(3-Fluoro-phenyl)-6-trifluoromethyl-pyridin-3-yl]-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, (,R)-N-[ 1 -(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-[2-piperid-1 -yl~6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-[2-piperid-l-yl~6-trifluoromethyl- pyridin-3 -yl] -acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-propylthio-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-propylthio-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylarnide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-5-methyl-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-trifluoromethyl-benzyl)-3-(2-phenethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Benzylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-5- methyl-benzyl)-acrylamide, (R)-3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, (R)-3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- benzyl)-acrylamide, (R)-3-(2-Benzylamino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylatnide, 3-(2-Benzylamino-6-trifluoromcthyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-pentyl-6- trifluoromethyl-pyridin-3 -y l)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-pentyl-6-trifluoromethyl-pyridin- 3-yi)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-bcnzyl)-3-(2-pentyI-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-[2-(3-fluoro-phenyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4- mcthanesulfonylamino-benzyl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-phenethyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy-ethylamino)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4-methanesulfonylamino- benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-propyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-propyl-6-trifluoromethyl- pyridin-3 -yl )-acrylamide, N-(4-Methancsulfonylamino-3-methyl-benzyl)-3-(2-propyl-6-trifluoromethyl-pyridin- 3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6- trifluoromethy l-pyridin-3 -yl)-acrylamide (R)-3-(2-sec-Butylamino-6-trifluorometihyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, (R)-N-[ 1 -(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3 -[2-(2-methyl-butyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-[2-(2-methoxy- ethylamino)-6-trifluoromethyl-pyridin-3-yl]-acrylamide, (R)-3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-[ 1 -(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-pentyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-pentyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Isopropylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-raethanesulfonylamino-benzyl)-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-propylammo-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-isobutyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, (R)-N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropylamino- 6-trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, (R)-N-[ 1 -(3,5 -Difluoro-4-methanesulfonylamino-phenyl)-ethyl] -3 -(2-propyIamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[ 1 -(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesidfonylamino-benzyl)-3-(2-isopropyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, 3-(2-Isopropyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- benzyl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropyl-6- trifluoromethyI-pyridin-3-yl)-acrylamide, 3 -(2-sec-Butyl-6-trifluoromethyl-pyridin-3 -y l)-N-(3,5-difluoro-4- methanesulfonylamino-benzyl)-acrylamide, (R)-N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-phenethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-phenethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-piperid-l-yl-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, and (5)-3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylaniide, including isomers, racemic mixtures and pharmaceutically acceptable salts thereof. Preferred examples of compounds according to the invention are selected from the group consisting of; N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-sec-Butoxy-6-trifluoromethyl-pyridin-3-yl)-N-(3-cyano-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-ButyIamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Cyano-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, 3 -(2-sec-Butylamino-6-trifluoromethy l-pyridin-3 -yl)-N-(3 -fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-cyano-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3 -(2-sec-Buty lamino-6-trifluoromethyl-pyridin-3 -y l)-N-(3 -fluoro-4- methanesnlfonylamino-5-methyl-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-bcnzyl)-3-(2-phenethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-{2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isobutyl-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methyl-butyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-[2-(methyl-phenyl-amino)- 6-trifluoromethyl-pyridin-3-yl]-acrylamide, N-(4-Melhanesulfonylaniino-3-methyl-benzyl)-3-(2-phenethyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, 3-(2-Isobutyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- bcnzyl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-sec-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-5-methyl-benzyl)-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-5- methyl-benzyl)-acrylamide, (R)-3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- benzyl)-acrylamide, (R)-3-(2-Benzylamino-6-trifluoromethyl-pyridin-3-yl)-N-[ 1 -(3-fluoro-4- methanesuifonylamino-phenyl)-ethyl]-acrylamide, 3 -(2-Benzylamino-6-trifluoromethyl-pyridin-3 -yl)-N-(3 -ethynyl-5 -fluoro-4- methanesulfonylaraino-benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-pentyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-pentyl-6-trifluoromethyl-pyridin- 3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-pentyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, 3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-phenethyl-6-trifluoromethyl- pyridin-3 -y l)-acry lamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-[2-(2-methoxy-ethylamino)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-(3,5-difluoro-4-methanesulfonylamino- benzyl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-propyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-propyl-6-trifluoromethyl- pyridin-3 -yl)-acry lamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-propyl-6-trifluoromethyl-pyridin- 3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-3-(2-sec-Butylainino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-[2-(2-methyl-butyl)-6- trifluoromethyl-pyridin-3-yl]-acrylamide, (R)-3-(2-Butylamino-6-trifluoromethyl-pyridin-3 -yl)-N-[ 1 -(3 -fluoro-4- methanesulfonylamino-phenyl)-cthyl]-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-pentyl-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-pentyl-6- trifluoromethyl-pyridin-3-yl)'acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Isopropylamino-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-isopropylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3 -Ethynyl-5 -fluoro-4-methanesulfonylamino-benzy l)-3 -(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Fluoro-4-mcthanesulfonylamino-5-methyl-benzyl)-3-(2-propylamiBO-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(4-Methanesulfonylamino-3-methyl-benzyl)-3-(2-propylamino-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, (R)-N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropylamino- 6-trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, (R)-N-[l-(3,5-Difluofo-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propylamino-6- trifluoromethyl-pyridin-3 -yl)-acrylamide, (R)-N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-isopropyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Isopropyl-6-trifluoromethyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-methyl- benzyl)-acrylamide, (R)-N-[l-(3-Fluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-isopropyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-N-[l-(3,5-Difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-phcnethyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, and (R)-3-(2-Butylamino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, including isomers, racemic mixtures and pharmaceutically acceptable salts thereof. Preferred examples of compounds according to the invention are selected from the group consisting of; (R)-N-[l-(3,5-Difluoro-4-methanesultbnylamino-phenyl)-ethyl]-3-(2-isobutyl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, (R)-3-(2-Ethylamino-6-trifluoromethyl-pyridin-3-yl)-N-[l-(3-fluoro-4- methanesulfonylamino-phenyl)-ethyl]-acrylamide, 3-(2-Ethylamino-6-trifluoromethyl-pyridin-3-yl)-N-l-(4-methanesulfonylamino-3- methyl-benzyl)-acrylamide, N-(2,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-propylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Ethylamino-6-trifluoromethyl-pyridin-3 -yl)-N-(3 -ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, 3-(2-Ethylamino-6-trifluoromethyl-pyridin-3-yl)-N-(3-ethenyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide, N-(4-Methanesiilfonylamino-benzyl)-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)- acrylamide, N-(3-Chloro-4-methanesulfonylamino-benzyl)-3-(2-propyl-6-trifluoromethyl-pyridin- 3 -yl)-acrylamide, N-(3-Chloro-4-methanesulfonylamino-benzyl)-3-(2-propylamino-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(2,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-ethylamino-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-(2-ethylamino-6-trifluoromethyl- pyridin-3 -yl)-acrylamide, N-(3,5-Difluoro-4-methanesulfonylamino-benzyl)-3-(2-ethylamino-6-trifluoromethyI- pyridin-3 -yl)-acrylamide, N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-ethylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, N-(3-Cano-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-ethylamino-6- trifluoromethyl-pyridin-3-yl)-acrylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-propynoic acid 3,5-difluoro-4- methanesulfonylamino-benzylamide, 3-(2-Butyl-6-trifluoromethyl-pyridin-3-yl)-propynoic acid [l-(3,5-difluoro-4- methanesulfonylamino-phenyl)-ethyl]-amide, N-(4-Methanesulfonylamino-benzyl)-3-(2-phenethyl-6-trifluoromethyl-pyridin-3-yl)- acrylamide, N-(4-Ethenesulfonylamino-benzyl)-3-(2-isoproylamino-6-trifluoromethyl-pyridin-3- yl)-acrylamide, (Z)-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-hex-2-enoic acid 3-ethynyl-5-fluoro-4- methanesulfonylamino-benzylamide, (E)-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-hex-2-enoic acid 3-ethynyl-5-fluoro-4- methanesulfonylamino-benzylamide, (Z)-3 -(2-propyl-6-trifluoromethyl-pyridin-3 -yl)-hex-2-enoic acid [1 -(3,5-difluoro-4- methanesulfonylamino-phenyl)-cthyl]-amide, (E)-3 -(2-propyl-6-trifluoromethyl-pyridin-3 -yl)-hex-2-enoic acid [ 1 -(3,5 -difluoro-4- methanesulfonylamino-phenyl)-ethyl]-amide, and N-(3-Ethenyl-5-fluoro-4-methanesidfonylamino-benzyl)-3-(2-morpholin-l-yl-6- trifluoromethyl-pyridin-3-yl)-acrylamide, including isomers, racemic mixtures and pharmaceutically acceptable salts thereof. Another aspect of the present invention relates to compounds of formula III, an isomer or a pharmaceutically acceptable salt thereof, wherein, R1 IS hydrogen or methyl; R2 is hydrogen; R3 is hydrogen, fluoro, chloro, methyl, cyano, ethenyl, or ethynyl; R4 is hydrogen R5 is fluoro, chloro, or methyl, preferably fluoro; R6 is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3- methylbutyl, n-pentyl, ethoxymethyl, 2-phenylethyl, phenylethenyl, phenyl, fluorophenyl, thienyl, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, 3- metylbutoxy, 2,2,2-trifluoroethoxy, cyclopentoxy, cyclopropylmethoxy, phenoxy, ethylthio, propylthio, isopropylthio, ethylamino, n-propylamino isopropylamino, n- butylamino, isobutylamino, sec-butylamino, methoxymethylamino, methoxyethylamino, ethoxyethylamino, cyclopentylamino, benzylamino, phenylamino, N-ethyl-N-phenylamino, N-methyl-N-phenylamino, N-methyl-N-propylamino, N-pyrrolidinyl, N-piperidyl, or ethoxycarbonyl N-piperidyl, and wherein Re preferably is n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, 2-phenylethyl, n-butoxy, isobutoxy, sec-butoxy, ethylamino, n-propylamino, isopropylamino, n-butylamino, isobutylamino, sec-butylamino, methoxyethylamino, ethoxyethylamino, benzylamino, N-ethyl-N-phenylamino, or N-methyl-N-phenylamino; R7 is halo(Cl-C3)alkyl, preferably CF3; R8 and R9 are independently hydrogen, halogen or trifluoromethyl, wherein R8 preferably represents hydrogen or chloro, and R9 is hydrogen; R10 IS methyl; and R11 t and R12 are hydrogen. Another aspect of the present invention is a compound having the formula IV, an isomer, or a pharmaceutically acceptable salt thereof. (Formula Removed) wherein, R1 IS hydrogen, methyl, or ethyl; R12 is hydrogen or C1-C3 alkyl, preferably hydrogen or propyl; R6 is C2-C6 alkyl, di (C1-C6 alkyl)amino, C1-C6 alkoxy, 2,2,2-trifluoro(Cl-C3)alkoxy, C1-C3 alkoxy (C1-C5) alkylamino, C1-C6 alkylamino, C3-C6 cycloalkylamino, phenoxy, phenylamino, phenyl(Cl-C3)alkylamino, phenyl(Cl-C3)alkyl, N-phenyl-N-(Cl-C5)alkylamino, methoxy-N-pyrrolidinyl, or C1-C6 alkylthio; R7 is CF3, CF2C1, or CF2CF3; and R8 and R9 are independently hydrogen, CF3, or halogen. In a particular aspect of the present disclosure, the compound of formula IV, is as described above, wherein, R1 IS hydrogen or methyl; R6 is C2-C5 alkyl, C1-C4 alkylamino, methoxy, or methoxyethylamino; R7 is CF3, Rg and R9 are all hydrogen; and R12 is hydrogen. Another aspect of the present invention is a compound having the formula V, an isomer, or a pharmaceutically acceptable salt thereof, (Formula Removed) wherein, R1 IS hydrogen, methyl, or ethyl; R3 is hydrogen, fluoro, or chloro; R6 is C2-C6 alkyl, di (C1-C6 alkyl)amino, C1-C6 alkoxy, 2,2,2-trifluoro(Cl-C3)alkoxy, C1-C3 alkoxy (C1-C5) alkylamino, C1-C6 alkylamino, C3-C6 cycloalkylamino, phenoxy, phenylamino, phenyl(Cl-C3)alkylamino, phenyl(Cl-C3)alkyl, or N-phenyl-N-(Cl-C5)alkylamino; R7 is CF3, CF2C1, or CF2CF3; R8 and R9 are independently hydrogen, CF3 or halogen; and R12 is hydrogen or C1-C3 alkyl, preferably hydrogen or propyl. In one specific aspect of the invention, the compound of formula V. is as described above, wherein, R1 IS hydrogen or methyl; R3 is hydrogen or fluoro; R6 is C2-C5 alkyl, C1-C4 alkylamino, methoxy, or methoxyethylamino; R7 is CF3; R8 and R9 are both hydrogen.; and R12 is hydrogen. Another aspect of the present invention relates to a compound having the formula VI, an isomer or a pharmaceutically acceptable salt thereof (Formula Removed) wherein, W is hydrogen or fluoro; X is -CR11=CR12- or -C=C-; R1 IS selected from hydrogen and C1-C3 alkyl; R6 is hydroxy, halogen, nitro, carboxy, C1-C10 alkyl, C1-C10 alkoxy, C2-C10 alkenyl, C2-C10 alkynyl, C1-C10 alkylthio, C1-C10 alkylsulfonyl, C1-C10 alkylcarbonyl, C1-C10 alkoxycarbonyl, C2-C10 alkenyloxy, C1-C5 alkoxy (Cl- C5) alkoxy, C1-C5 alkoxy (C1-C5) alkoxy (C1-C5) alkyl, piperidyl, C1-C5 alkoxy (C1-C5) alkylamino, C1-C10 alkylamino, di(Cl-C10 alkyl)amino, C3-C8 cycloalkyl, C3-C8 cycloalkylamino, C3-C8 cycloalkoxy, C3-C8 oxacycloalkyl- oxy, N-(Cl-C5)alkoxy (C1-C5) alkyl-N-(C1-C5) alkylamino, N-(C3- C8)cycloalkyl-N-(Cl-C5) alkylamino, N-aryl-N-(Cl-C5) alkylamino, preferably N-phenyl-N-(Cl-C5)aIkylamino, aryl preferably phenyl, arylamino preferably phenylamino, heteroaryl preferably thienyl, heteroarylamino, aryloxy preferably phenoxy, pyrrolidinyl, or morpholinyl; R11 AND R12, if present, are independently selected from hydrogen and C1-C3 alkyl, preferably hydrogen or propyl, R7 is CF2CF3,CF2C1 or, preferably, CF3; R8 and R9 are independently selected from hydrogen, halogen or CF3; wherein, - each alkyl, alkenyl and alkynyl, also as a part of a group such as in alkoxy, alkylsulfonyl, alkylcarbonyl, alkylamino, or alkenyloxy may be independently unsubstituted or substituted with one or more substituents selected from among halogen, hydroxyl, unsubstituted or halo-substituted (C1-C5) alkoxy, (C3-C8) cycloalkyl which may be unsubstituted or substituted with one or two halogen radicals and/or methyl groups, unsubstituted or halo-substituted (C1-C5) alkylamino, phenyl which may be unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C3 alkyl, or halo (C1-C3) alkyl, or unsubstituted or halo-substituted di(C1-C5) alkylamino, - each aryl or heteroaryl, also a part of a group such as in arylamino, aryloxy, heteroaryloxy, or heteroarylamino, may be independently unsubstituted or substituted with one or more substituents selected from halogen, unsubstituted C1-C5 alkyl, unsubstituted C1-C5 alkoxy, or halo (C1-C5) alkyl, each cycloalkyl, also as a part of a group such as in cycloalkoxy or cycloalkylamino may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups, hydroxymethyl, hydroxy, methoxy, or amino, and - each piperidyl, or morpholinyl may be unsubstituted or substituted with one or more unsubstituted or halo-substituted C1-C3 alkyl groups. hydroxy(Cl-C3)alkyl, C1-C3 alkoxy, (Cl-C3)alkoxycarbonyl, or hydroxyl. One aspect of the present inventions are compounds of the general formula VI, as described above wherein • R8 and R9 are both hydrogen, and/or • X is -CH=CH-, and/or • X is -CH=CH-, and W, Rg and R9 are both hydrogen, and/or • R1 IS hydrogen or methyl; and/or •• R6 is selected from C2-C6 alkyl, di (C1-C6 alkyl)amino, 2,2,2- trifluoro(C 1 -C3)alkoxy, C1-C3 alkoxy (C 1-C5) alkylamino, C1-C6 alkylamino, C3-C6 cycloalkylamino, phenyl, phenylamino, phenyl(Cl-C3)alkylamino, phenyl(Cl-C3)alkyl, orN-phenyl-N-(Cl-C5)alkylamino, wherein each phenyl can be substituted with one or more halogens; and/or • R7 is CF3 Another aspect of the present inventions are compounds of the general formula VI, as described herein wherein • R1 IS hydrogen or methyl; and/or • R6 is selected from C2-C5 alkyl, C1-C4 alkylamino, or methoxyethylamino; preferably R6 is -NH-(C1-C4) alkyl, or linear or branched C2-C5 alkyl; and/or • R7 is CF3; and/or • R12 is hydrogen. Another preferred embodiment of the invention is a compound of formula VI, as described above, wherein • W, R8, and R9 are all hydrogen; • X is -CH=CH-; • R6 is selected from C2-C5 alkyl, C1-C4 alkylamino, or methoxyethylamino; preferably R« is -NH-(C1-C4) alkyl, or linear or branched C2-C5 alkyl; • R1 IS hydrogen, or methyl; and • R7 is CF3. Another aspect of the present invention relates to Compounds of formula I, III, IV, V, or VI as described herein, wherein R1 IS hydrogen, methyl or ethyl, preferably hydrogen or methyl. In more specific embodiments, wherein if R1 IS methyl or ethyl, then the atom to which R1 IS attached is preferably in (R)-configuration. The compounds of the formula (I). (II), (III), (IV), (V), and (VI) of the present invention can chemically be synthesized by the following reaction schemes. However, these are given only for illustration of the invention and not intended to limit to them. [Scheme 1] (Scheme Removed) The Scheme 1 shows a proposed process for synthesizing acrylamide compound with various substituents. Substituted benzylamine (1) is reacted with pyridinyl acrylic acid (2) to yield benzyl pyridinyl acrylamide (3) using DMTMM {4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methylmorpholinium chloride} (Tetrahedron Lett., 1999, 40, 5327). {Scheme 2] (Scheme Removed) The Scheme 2 shows a proposed process for synthesizing pyridinyl acrylic acid (9) with various substituents. Substituted pyridinecarboxaldehyde (7) is prepared by known methods. Substituted nicotinic acid (4) or nicotinic ester (5) is converted to corresponding pyridinecarboxaldehyde (7) via pyridinyl methyl alcohol (6). Pyridinyl methyl alcohol is converted to pyridinecarboxaldehyde (7) via Swern oxidation. Pyridinecarboxaldehyde (7) is converted to methyl pyridinyl acrylic ester (8) by Wittig reaction. Methyl pyridinyl acrylic ester (8) is hydrolyzed with potassium hydroxide to yield pyridinyl acrylic acid (9). [Scheme 3] (Scheme Removed) The Scheme 3 shows a proposed process for synthesizing pyridinyl acrylic amide (16) with t-butyl group. Substituted pyridinecarboxaldehyde with t-butyl group (12) is prepared by reduction followed by radical substitution method (J. Heterocyclic Chem., 1989, 25, 45-48). Substituted nicotinic ester (10) is converted to corresponding pyridine-3-methanol (11). Pyridinyl-3-methanol is reacted with pivalic acid and silver nitrate to give pyridinecarboxaldehyde (12) via Tada's radical substitution. Compound (14) is synthesized from compound (12) with similar method of scheme 2. 4-t-Butylpyridinyl acrylic acid (14) is reacted with compound (15) to yield compound (16), [ Scheme 4] (Scheme Removed) The Scheme 4 shows a proposed process for synthesizing pyridinyl acrylicamide (22) with trifluoromethyl group on pyridine. 2-Chloro-6-trifluoromethyl-nicotinic ester (17) is reacted with cyclic secondary amine to give compound (18). Compound (18) is converted to compound (21) following similar reaction of scheme 2. Compound (21) is reacted with compound (15) to give compound (22). [Scheme 5] (Scheme Removed) The Scheme 5 shows a proposed process for synthesizing pyridinyl acrylamide (28). 2-Chloro-nicotinic acid compound (23) is reacted with N,O-dimethylhydroxylamine hydrochloride to give compound (24). Compound (24) is reduced with LAH to afford compound (25), which is converted to methyl pyridinyl acrylic ester (26) by Wittig reaction. Compound (26) is hydrolyzed using LiOH to give pyridinyl acrylic acid (27), which is then reacted with compound (15) to give compound (28). [Scheme 6] (Scheme Removed) The Scheme 6 shows a proposed process for synthesizing pyridinyl acrylic ester or pyridinyl acrylic acid (30) or (31) with 2-alkylamino group or 2-alkoxy group on pyridine, respectively. Compound (29) is reacted with various amine or alcohol to give compound (30) or compound (31) with or without using a base such as K2CO3 or NaH. [Scheme 7] acrylic acid methyl ester (38). 3-(2-Alkyl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (39) obtained by hydrolyzing the compound (38) with LiOH is reacted with the amine compound (1) to yield pyridinyl acrylamide (40) with 2-alkyl group on pyridine. [Scheme 9] (Scheme Removed) The Scheme 9 shows a proposed process for synthesizing pyridinyl acrylamide (44) with 2-aryl or 2-heteroaryl on pyridine. Compound (42) obtained by Suzuki coupling of compound (41) with various boronic acids using microwave irradiation is hydrolyzed with LiOH to yield acrylic acid (43). Acrylic acid (43) is then reacted with the compound (1) to give pyridinyl acrylamide (44) with 2-aryl or 2-heteroaryl group on pyridine. [Scheme 10] (Scheme Removed) The Scheme 10 shows another proposed process for synthesizing pyridinyl acrylamide (49) with 2-alkyl group on pyridine. Compound (46) obtained by Sonogashira coupling of compound (45) with various alkynes using microwave irradiation is reduced by hydrogenation to yield Weireb amide (47). The amide (47) is reduced to aldehyde, and the resulting aldehyde is subjected to Wittig reaction followed by hydrolysis with LiOH to afford acrylic acid (48). Acrylic acid (48) is then reacted with the compound (1) to give pyridinyl acrylamide (49) with 2-alkyl group on pyridine. [Scheme 11] (Scheme Removed) The Scheme 11 shows a proposed process for synthesizing pyridinyl acrylamide (53) with 2-alkylsulfinyl or 2-arylsufinyl group on pyridine. Compound (50) obtained by the reaction of compound (45) with various alkylthiols or arylthiols using NaH is reduced with lithium aluminum hydride to give an aldehyde, and the resulting aldehyde is subjected to Wittig reaction to give the compound (51). Compound (51) is hydrolyzed with LiOH to afford acrylic acid (54). Acrylic acid (54) is then reacted with the compound (1) to give pyridinyl acrylamide (55) with 2-alkylthio or 2-arylthio group on pyridine. {Scheme 12] (Scheme Removed) The Scheme 12 shows a proposed process for synthesizing pyridinyl acrylamide (56) with 2-alkylsulfonyl or 2-arylsulfonyl group on pyridine. Compound (55) is oxidized with mCPBA to give pyridinyl acrylamide (56) with 2-alkylsulfonyl or 2-arylsufonyl group on pyridine. [Scheme 13] (Scheme Removed) The Scheme 13 shows a proposed process for synthesizing pyridinyl acrylamide (59) with 2-styryl group on pyridine. Compound (57) obtained by the Heck reaction of compound (41) using microwave irradiation is hydrolyzed with LiOH to afford acrylic acid (58). Acrylic acid (58) is then reacted with the compound (1) to give pyridinyl acrylamide (59) with 2-styryl group on pyridine. [Scheme 14] (Scheme Removed) The Scheme 14 shows a proposed process for synthesizing pyridinyl acrylamide (64). 2-Chloro-nicotinic acid compound (23) is reacted with various amines to yield nicotinic acid compound (60) with 2-alkylamino, 2-dialkylamino, 2-arylamino, or 2-N-alkyl-N-aryl-amino group, which undergoes similar reactions to scheme 5 to give pyridinyl acrylic acid (63). Pyridinyl acrylamide (64) is then obtained by the reaction of pyridinyl acrylic acid (63) with the amine compound (1). [Scheme 15] (Scheme Removed) The Scheme 15 shows another proposed process for synthesizing 2-alkyl-6-trifluoromethyl-nicotinic acid alkyl ester (36). 3-Amino-alk-2-enoic acid, alkyl ester (65) is reacted with compound (66) to yield 2-alkyl-6-trifluoromethyl-nicotinic acid alkyl ester (36). (Scheme 16] (Scheme Removed) The Scheme 16 shows another proposed process for synthesizing 3-(2-alkyl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid methyl ester (38). 2-alkyl-6-trifluoromethyl- nicotinic acid alkyl ester (36) is treated with a base such as LiOH to yield the corresponding acid, which was reacted with N,O-dunethylhydroxylamine hydrochloride to give the amide compound (67). The compound (67) is reduced with LAH to yield the corresponding aldehyde, which is converted to 3-(2-alkyl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid methyl ester (38) by Wittig reaction. [ Scheme 17] (Scheme Removed) The Scheme 17 shows a proposed process for synthesizing 3-pyridin-3-yl-propynoic acid, benzylamide (71). The Weinreb amide (67) is reduced with LAH to yield the corresponding aldehyde, which is convered to the dibromide compound (68). The compound (68) is treated with BuLi followed by methyl chloroformate to yield 3-pyridin-3-yl-propynoic acid, methyl ester (69), which is then converted to 3-pyridin-3-yl-propynoic acid(70) using LiOH. 3-Pyridin-3-yl-propynoic acid, benzylamide (71) is obtained by reacting the propynoic acid (70) with the amine compound (1). [Scheme 18] (Scheme Removed) The Scheme 18 shows a proposed process for synthesizing pyridinyl acrylamide (76). Diketone (72) is reacted with compound (35) to yield pyridinyl ketone compound (73), which is transformed to the pyridinyl acrylonitrile compound (74) by reacting with cyanomethylphosphonic acid diethyl ester and NaH. 3-(2-Alkyl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (75) obtained by hydrolyzing the pyridinyl acrylonitrile compound (74) with KOH is reacted with the amine compound (1) to yield pyridinyl acrylamide (76). [Scheme 19] (Scheme Removed) The Scheme 19 shows a proposed process for synthesizing acrylamide compound with various substituents. Substituted benzylamine (77) is reacted with pyridinyl acrylic acid (2) to yield benzyl pyridinyl acrylamide (78) using DMTMM. The present invention also provides a compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof for preventing or treating a disease associated with the pathological stimulation and/or aberrant expression of vanilloid receptor, wherein said composition comprises the compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable carrier. In one preferred aspect, the present invention provides a compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof for treating a condition selected from the group consisting of pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis, pancreatitis, vulvodynia, haemorrhagic shock, and psychiatric disorders such as anxiety or fear. In a particularly preferred aspect, the present invention relates to a compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof, wherein the pain is or is associated with a condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, diabetic neuropathic pain, post-operative pain, dental pain, non-inflammatory musculoskeletal pain (including fibromyalgia, myofascial pain syndrome and back pain), migraine, other types of headaches, bone cancer pain, mastalgia and visceral pain. The present invention also provides a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV), (V). or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient together with a pharmaceutically acceptable carrier. The present invention also provides a pharmaceutical composition for preventing or treating a disease associated with the pathological stimulation and/or aberrant expression of vanilloid receptor, wherein said composition comprises the compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable carrier. In one preferred aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof, for treating a condition selected from the group consisting of pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis, pancreatitis, vulvodynia, haemorrhagic shock, and psychiatric disorders such as anxiety or fear. In a particularly preferred aspect, the present invention relates to the pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof for treating pain as described above, wherein the pain is or is associated with a condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, diabetic neuropathic pain, post-operative pain, dental pain, noninflammatory musculoskeletal pain (including fibromyalgia, myofascial pain syndrome and back pain), migraine, other types of headaches, bone cancer pain, mastalgia, and visceral pain. The present invention also provides a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof, which is characterized in that it is adapted for oral administration. In another aspect, the present invention relates to a method for inhibiting vanilloid ligand from binding to vanilloid receptor in a patient, comprising contacting cells expressing vanilloid receptor in the patient with the compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof. In another aspect, the present invention also provides a method for preventing or treating a condition selected from the group consisting of pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis, pancreatitis, vulvodynia, haemorrhagic shock, and psychiatric disorders such as anxiety or fear, which comprises administering to a mammal including a person in need thereof a therapeutically effective amount of the compound of formula (I), (II), (HI), (IV), (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof. In a particularly preferred aspect, the present invention relates to the method of treating pain by administering a compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof as described above, wherein the pain is or is associated with a condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, ankylosmg spondylitis, diabetic neuropathic pain, post-operative pain, dental pain, non-inflammatory musculoskeletal pain (including fibromyalgia, myofascial pain syndrome and back pain), migraine, other types of headaches, bone cancer pain, mastalgia, and visceral pain. In another aspect, the present invention relates to the use of a compound of formula (I), (II), (III), (IV) , (V), or (VI),an isomer thereof, or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the prevention or treatment of a condition that is associated with the aberrant expression and/or aberrant activation of a vanilloid receptor. In another aspect, the present invention relates to the use of a compound of formula (I), (II), (III), (IV) , (V), or (VI), an isomer thereof, or a pharmaceutically acceptable salt thereof, in preparation of a medicament for the prevention or treatment of a condition that is selected from the group consisting of pain, inflammatory disease of the joints, neuropathies, HIV-related neuropathy, nerve injury, neurodegeneration, stroke, urinary bladder hypersensitivity including urinary incontinence, cystitis, stomach duodenal ulcer, irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), fecal urgency, gastro-esophageal reflux disease (GERD), Crohn's disease, asthma, chronic obstructive pulmonary disease, cough, neurotic/allergic/inflammatory skin disease, psoriasis, pruritus, prurigo, irritation of skin, eye or mucous membrane, hyperacusis, tinnitus, vestibular hypersensitivity, episodic vertigo, cardiac diseases such as myocardial ischemia, hair growth-related disorders such as effluvium, alopecia, rhinitis, pancreatitis, vulvodynia, haemorrhagic shock, and psychiatric disorders such as anxiety or fear. In a particularly preferred aspect, the present invention relates to the use of the compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof, for preparing a medicament for preventing or treating pain as described above, wherein the condition is pain or which is or which is associated with a condition selected from the group consisting of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, diabetic neuropathic pain, post-operative pain, dental pain, non-inflammatory musculoskeletal pain (including fibromyalgia, myofascial pain syndrome and back pain), migraine, other types of headaches, bone cancer pain, mastalgia, and visceral pain. The present invention also provides a process for preparing a compound represented by the formula (III) (Formula Removed) which comprises reacting a compound represented by the formula (IIIa); (Formula Removed) with a compound represented by the formula (IIIb); (Formula Removed) wherein, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, and R12 are as described in any of the preceding embodiments. One preferred aspect of the present invention is the process for preparing a compound of formula (III), wherein, the reaction is conducted in the presence of a coupling agent. Another preferred aspect of the present invention is the process for preparing a compound of formula (III), wherein the coupling agent is selected from the group consisting of DCC (N,N-dicyclohexylcarbodidimide), EDCI (l-(3-dimethylaminopropyl)-3-ethylcarbodidimide hydrochloride (EDCI)}, and DMTMM {4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride}. The present invention also provides a process for preparing a compound of formula (IIIc), (Formula Removed) which comprises a reducing step of the compound of the formula (III). One preferred aspect of the present invention is the process for preparing a compound of formula (IIIc), wherein the reducing step is conducted in the presence of hydrogen gas and palladium on carbon. Another preferred aspect of the present invention is the process for preparing a compound of formula (III) or (IIIc), wherein R1, R11, and R12 are hydrogen. Another preferred aspect of the present invention is the process for preparing a compound of formula (HI) or (IHc), wherein, R1, R2, R8, R11, and R12 are hydrogen; R3 is hydrogen, fluoro, chloro, bromo, cyano, methyl, ethyl, ethenyl, ethynyl, or trifluoromethyl; R4 and RS are independently hydrogen, fluoro, chloro, cyano, methyl, ethyl, or trifluoromethyl; R6 is hydrogen, fluoro, chloro, bromo, methyl, methoxy, diethylamino, pyrrolidinyl, piperidyl, or morpholinyl; R/ is isopropyl, t-butyl, or trifluoromethyl; Rg is hydrogen or trifluoromethyl; and R10 IS methyl. The present invention also provides a novel compound of formula (IIId) (Formula Removed) wherein, W is hydrogen or fluoro; R1 IS hydrogen or C1-C3 alkyl, preferably methyl; and R10 IS C1-C3 alkyl, C2-C3 alkenyl, or halo C1-C3 alkyl, preferably methyl; provided that if R1 IS hydrogen and R10 IS methyl, then W is fluoro. Specific examples of compounds of formula (Hid) are: (R)-N-[4-( 1 -amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide, HCI salt, (R)-N-[4-( 1 -amino-propyl)-2,6-difluoro-phenyl]-methanesulfonamide, HCI salt, N-(4-aminomethyl-2,3,6-trifluoro-phenyl)-methanesulfonamide, HCI salt, (R)-N-[4-(l -amino-ethyl)-2,3,6-trifluoro-phenyl]-methanesulfonamide, HCI salt, (R)-N-[4-(l-amino-propyl)-2,3,6-trifluoro-phenyl]-methanesulfonamide, HCI salt, N-(4-aminomethyl-2,6-difluoro-phenyl)-ethnesulfonamide, HC1 salt, (R)-N-[4-( 1 -amino-ethyl)-2,6-difluoro-phenyl]-ethenesulfonamide, HC1 salt, (R)-N-[4-(l -amino-propyl)-2,6-difluoro-phenyl]-ethenesulfonamide, HC1 salt, N-(4-aminomethyl-2,3,6-trifluoro-phenyl)-ethnesulfonaniide, HC1 salt, (R)-N-[4-(l-amino-ethyl)-2,3,6-trifluoro-phenyl]-ethenesulfonamide, HC1 salt, or (R)-N-[4-(l-amino-propyl)-2,3,6-trifluoro-phenyl]-ethenesulfonamide, HC1 salt. Another aspect of the present invention is the use of the compound of formula (Hid) as described above as an intermediate in the production of a compound of a VR1 ligand, preferably of the general formula I, III or most preferably VI, as described in this application, wherein W is hydrogen or fluoro. Another embodiment of the present invention is a process for preparing a compound of formula (IIId), wherein R1 is C1-C3 alkyl, preferably methyl, said process comprising: (a) reacting a compound of Formula (IIIe) (Formula Removed) wherein, W is as defined as above, with a compound of Formula (IIIf) (Formula Removed) wherein, A is I or Br, in the presence of an acid in a solvent to afford a compound of Formula (Illg) (Formula Removed) wherein, W and A are as defined above; (b) reacting a compound of Formula (Illg) with a compound of Formula (IIIh) (Formula Removed) wherein, R13 is hydrogen or C1-C2 alkyl, preferably hydrogen, in the presence of a catalyst and a ligand in a solvent to afford a compound of Formula (IIIi); (Formula Removed) wherein W and R1 are as defined above; (c) reacting a compound of Formula (Hli) with a compound of Formula (IIIj) (Formula Removed) wherein, R10 IS as defined above, in the presence of a base in a solvent followed by NaOH in a solvent to afford a compound of Formula (IIIk) (Formula Removed) wherein, W, R1 and R10 are as defined above; (d) reacting a compound of Formula (Illk) with (R)-(+)-2-methyl-2- propanesulfmamide in the presence of an acid in a solvent followed by NaBH4 in a solvent and then HC1 in a solvent to afford a compound of Formula (Hid), wherein, W and RIO are as defined above, and R1 IS C1-C3 alkyl, preferably methyl. Another embodiment of the present invention is a process for preparing a compound of formula (Hid), wherein R1 IS hydrogen, said process comprising: (a) reacting a compound of Formula (Illg) (Formula Removed) wherein, W and A are as defined above with CuCN in a solvent to afford a compound of Formula (Him) (Formula Removed) wherein, W is as defined above; (b) reacting a compound of Formula (IIIm) with a compound of Formula (HIj) (Formula Removed) wherein, R10 IS as defined above, in the presence of a base in a solvent followed by NaOH in a solvent to afford a compound of Formula (Illn) (Formula Removed) wherein, W and R10 are as defined above; c) reacting a compound of Formula (Illn) with hydrogen in the presence of a catalyst and an acid in a solvent to afford a compound of Formula (Hid) (Formula Removed) wherein. W and RIO are as defined above, and R1 IS hydrogen. Hereinafter, the formulating methods and kinds of excipients will be described, but the present invention is not limited to them. A compound of formula (I), (II), (III), (IV), (V), or (VI), an isomer thereof or a pharmaceutically acceptable salt thereof according to the present invention can be prepared as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants, diluents and the like. For instance, the compounds of the present invention can be dissolved in oils, propylene glycol or other solvents which are commonly used to produce an injection. Suitable examples of the carriers include, but not limited to, physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc. For topical administration, the compounds of the present invention can be formulated in the form of ointment or cream. The compound according to the present invention may also be used in the forms of pharmaceutically acceptable salts thereof, and may be used either alone or in combination or in admixture with other pharmaceutically active compounds. The compounds of the present invention may be formulated into injections by dissolving, suspending or emulsifying in water-soluble solvent such as saline and 5% dextrose, or in water-insoluble solvents such as vegetable oils, synthetic fatty acid glyceride, higher fatty acid esters and propylene glycol. The formulations of the invention may include any of conventional additives such as dissolving agents, isotonic agents, suspending agents, emulsifiers, stabilizers and preservatives. The preferable dose level of the compounds according to the present invention depends upon a variety of factors including the condition and body weight of the patient, severity of the particular disease, dosage form, and route and period of administration, but may appropriately be chosen by those skIIIed in the art. The compounds of the present invention are preferably administered in an amount ranging from 0.001 to 100 mg/kg of body weight per day, and more preferably from 0.01 to 30 mg/kg of body weight per day. Doses may be administered once a day, or several tunes a day with each divided portions. The compounds of the present invention are used in a pharmaceutical composition in an amount of 0.0001 D10% by weight, and preferably 0.001 Dl% by weight, based on the total amount of the composition. The pharmaceutical composition of the present invention can be administered to a mammalian subject such as rat, mouse, domestic animals, human being and the like via various routes. The methods of administration which may easily be expected include oral and rectal administration; intravenous, intramuscular, subcutaneous, intrauterine, duramatral and intracerebroventricular injections. Detailed description of the invention definitions When describing the compounds, pharmaceutical compositions containing such compounds, methods of using such compounds and compositions, and use of such compounds and compositions, all terms used in the present application shall have the meaning usually employed by a relevant person skIIIed in the art, e.g. by a medicinal chemists, pharmacist or physician. By the way of example some definitions of specific groups are given below: "Alky!" includes monovalent saturated aliphatic hydrocarbyl groups. The hydrocarbon chain may be either straight-chained or branched. "Alkyl" has preferably 1-15 carbon atoms ("C1-C15 alkyl"), more preferably 1-10 carbon atoms ("C1-C10 alkyl"), even more preferably 1-8 carbon atoms ("C1-C8 alkyl") or 1-6 carbon atoms ("C1-C6 alkyl"), and in some instances even more preferably 1-5 carbon atoms ("Cl-C5 alkyl"), 1-4 carbon atoms ("C1-C4 alkyl"), or only 1-3 carbon atoms ("C1-C3 alkyl"). This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert-butyl, t-amyl, and the like. "Alkoxy" includes the group -OR wherein R is "alkyl" as defined further above. Particular alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, 1,2-dimethylbutoxy, and the like. "Alkoxyalkoxy" refers to the group -OROR', wherein R and R' are the same or different "alkyl" groups as defined further above. "Alkoxyalkoxyalkyl" refers to the group -ROR'OR", wherein R, R' and R" are the same or different "alkyl" groups as defined further above. "Alkoxyalkyamino" refers to the group -NH(ROR'), wherein R and R' are the same or different "alkyl" groups as defined further above. "N-Alkoxyalky-N-alkylamino" refers to the group -NR(R'OR"), wherein R, R' and R" are the same or different "alkyl" groups as defined further above. "Alkoxyalkynyl"' refers to the group c=*c (CH2)n°R, wherein n is an integer from 0 to 8 and R is an "alkyl" group as defined further above. "Dialkylaminoalkynyl" refers to the group "C≡C—(CH2)nNRR' wherein n is an integer from 0 to 8 and R and R' are the same or different "alkyl" groups as defined further above. "Alkoxycarbonyl" refer to the radical -C(=O)-O-R, wherein R is an alkyl group as defined herein. "Alkenyl" includes monovalent olefinically unsaturated hydrocarbyl groups being straight-chained or branched and having at least 1 double bond. "Alkenyl" has preferably 2-15 carbon atoms ("C2-C15 alkenyl"), more preferably 2-10 carbon atoms ("C2-C10 alkenyl"), even more preferably 2-8 carbon atoms ("C2-C8 alkenyl") or 2-6 carbon atoms ("C2-C6 alkenyl''), and in some instances even more preferably 2-5 carbon atoms ("C1-C5 alkenyl"), 2-4 carbon atoms ("C2-C4 alkenyl"), or only 2-3 carbon atoms ("C2-C3 alkenyl"). Particular alkenyl groups include ethenyl (-CH=CH2), n-propenyl (-CH2CH=CH2), isopropenyl (C (CH3) =CH2), and the like. A preferred "alkenyl" group is ethenyl (vinyl). "Alkynyl" includes acetylenically unsaturated hydrocarbyl groups being straight-chained or branched and having at least 1 triple bond. "Alkynyl" has preferably 2-15 carbon atoms ("C2-C15 alkynyl"), more preferably 2-10 carbon atoms ("C2-C10 alkynyl"), even more preferably 2-8 carbon atoms ("C2-C8 alkynyl") or 2-6 carbon atoms ("C2-C6 alkynyl"), and in some instances even more preferably 2-5 carbon atoms ("C1-C5 alkynyl"), 2-4 carbon atoms ("C2-C4 alkynyl"), or only 2-3 carbon atoms ("C2-C3 alkynyl"). A preferred alkynyl group is ethynyl (acetylenyl). "Alkylamino" includes the group -NHR', wherein R' is alkyl group as defined herein. "Dialkylamino" includes the group -NR'R", wherein R1 and R" are alkyl group as defined herein. "Alkylsulfonyl" includes a radical-S(O)2R, wherein R is an alkyl group as defined herein. Representative examples include, but are not limited to, methanesulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl and the like. "Alkylthio" includes a radical-S-R wherein R is an alkyl group as defined herein that may be optionally substituted as defined herein. Representative examples include, but are not limited to, methylthio, ethylthio, propylthio, butylthio, and the like. "Amino" refers to the radical-NHa -Aryl" refers to an aromatic hydrocarbyl radical. Examples of "aryl" radicals are phenyl, naphthyl, indenyl, azulenyl, fluorine or anthracene, wherein phenyl is preferred. "Arylamino" refers to the group -NHAr, wherein Ar is an "aryl" group as defined above. "Aryloxy" refers to the group -OAr, wherein Ar is an "aryl" group as defined above. "Carboxy" refers to the radical -C(=O)OH. "Cycloalkyl" refers to cyclic saturated aliphatic hydrocarbyl groups. The numbers of C-atoms referenced in connection with a given cycloalkyl group corresponds to the number of ring forming carbon atoms, e.g. "C3-C6 cycloalkyl" refers to a cycloalkyl with between three and six ring-forming C atoms. Examples of "cycloalkyl" are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl etc. If indicated, a •'cycloalkyl" group may be unsubstituted or substituted with one or more alkyl groups, e.g. with C1-C6 alkyl groups, preferably with C1-C3 alkyl groups, particularly preferably with methyl groups. If a "'cycloalkyl" carries more than one alkyl substituent these substituents may be attached to the same or to different ring-forming carbon atoms. "Cycloalkoxy" refers to the group -OR, wherein R is "cycloalkyl" group as defined further above. "Cycloalkylamino" refers to the group -NHR, wherein R is "cycloalkyl" group as defined further above. "N-Cycloalkylamino-N-alkylamino" refers to the group -NRR', wherein R is the same or different "alkyl" group as defined further above and R' is "cycloalkyl" group as defined further above. "N-aryl-N-alkylamino" refers to the group -NRAr, wherein Ar is an "aryl" group as defined above and R is an "alkyl" group as defined further above. "Oxacycloalkyl" refers to cyclic saturated aliphatic hydrocarbyl groups with one oxygen atom at any position in the ring. The numbers of C-atoms referenced in connection with a given oxacycloalkyl group corresponds to the number of ring forming carbon atoms, e.g. "C3-C6 oxacycloalkyl" refers to a oxacycloalkyl with between three and six ring-forming C atoms and one O atom. Examples of "oxacycloalkyl" are oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl etc. If indicated, a "oxacycloalkyl" group may be unsubstituted or substituted with one or more alkyl groups, e.g. with C1-C6 alkyl groups, preferably with C1-C3 alkyl groups, particularly preferably with methyl groups. If a "oxacycloalkyl" carries more than one alkyl substituent these substituents may be attached to the same or to different ring-forming carbon atoms. "Oxacycloalkyl-oxy" refers to the group -OR, wherein R is "oxacycloalkyl" group as defined further above. "Cyano" refers to the radical -C=N "Ethenyl" refers to -CH=CH2 which is also designated "vinyl'" in the present application. "Ethynyl" refers to -OCH. "Halo" or "halogen" refers to fluoro, chloro, bromo and iodo. Preferred halo groups are either fluoro or chloro. "Haloalkyl" includes an "alkyl" group as defined further above which is substituted with one or more halogens which may be the same, e.g. in trifluoromethyl or pentafluoroethyl, or which may be different. "Heteroaryl" refers to aromatic ring system containing at least one heteroatom such as O, S or N. Examples of heteroaryl radicals are furanyl, thienyl, pyrollyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, indolinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzoimidazolyl, benzthiazolyl, purinyl, quinazolinyl, quinolinyl, isoquinolinyl, quinolizinyl, pteridinyl, carbazolyl, wherein one ring sytems, and in particular pyridinyl and imidazolyl are preferred. "Heteroarylamino" refers to the group -NHAr', wherein Ar' is a "heteroaryl" group as defined above. "Heteroaryloxy" refers to the group -OAr', wherein Ar' is a "heteroaryl" group as defined above. "Hydroxy" refers to the radical-OH. "Hydroxyalkyl" includes an "alky!" group as defined further above which is substituted with one or more hydroxy groups. "Nitro" refers to the radical-NO2. "Alkylpiperazinyl" refers to a piperazine ring that carries an "alky!" as substituent, wherein the piperazinyl ring is preferably bound both to the "alkyl" as well as to the second attachment position via its nitrogen atoms. "Piperazinyl" comprises a piperazinyl ring that can be bound by any C-atom as well as by a nitrogen atom, wherein bondage via one of its nitrogen atoms is preferred. "Pyrrolidinyr comprises a pyrrolidine ring that can be bound by any C-atom as well as by its nitrogen atom, wherein bondage via its nitrogen atom is preferred. "Morpholinyl" comprises a morpholine ring that can be bound by any C-atom as well as by its nitrogen atom, wherein bondage via its nitrogen atom is preferred. "Pyridinyl" comprises a pyridine ring that can be bound by any C-atom as well as by its nitrogen atom. Any "alkyl", "alkenyl", "alkynyl", "aryl", "heteroaryl", "cycloalkyl", "piperazinyl", "piperidyl", "morpholinyl", or pyrrolidinyl", also as parts of larger groups such as "alkoxy", "alkylsulfonyl", "alkenyloxy", "aryloxy", "heteroaryloxy", "cycloalkylamino" etc. may be unsubstituted or substituted by one or more groups. Suitable substituents are e.g. halogen, hydroxyl, unsubstituted or halo-substituted C1-C5 alkoxy, unsubstituted or one or more times with methyl and/or with halogen substituted C3-C8 cycloalkyl, C1-C5 alkyl, halo (C1-C5) alkyl, amino, cyano, or nitro. Unless expressly specified otherwise, any "alkyl", "alkenyl", "alkynyl", "aryl", "heteroaryl", "cycloalkyl"', "piperazinyl", "piperidyl", "morpholinyl"', or pyrrolidinyl", (also as parts of a larger group) is preferably unsubstituted. "Isomer'" includes especially optical isomers (for example essentially pure enantiomers, essentially pure diastereomers, and mixtures thereof) as well as conformation isomers (i.e. isomers that differ only in their angles of at least one chemical bond), position isomers (particularly tautomers), and geometric isomers (e.g. cis-trans isomers). "Essentially pure", e.g. in connection with enantiomers or diastereomers means at least about 90%, preferably at least about 95%, more preferably at least about 97 or at least about 98%, even more preferably at least about 99%, and particularly preferably at least about 99.5% (w/w) of a specified compound, e.g. a particular enantiomer or diastereomer. "Pharmaceutically acceptable" means being devoid of substantial toxic effects when used in doses usually employed in a medicinal dosage, and thereby being approvable or preferably being approved by a regulatory agency of the Federal or a state government or being listed in the U. S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans. "Pharmaceutically acceptable salt" refers to a salt of a compound of the invention that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (I) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid,3- (4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, Inaphthalenesulfonic acid, 4-toluenesulfonic acid,camphorsulfonic acid, 4methylbicyclo [2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid,3-phenyipropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound is replaced. "Pharmaceutically acceptable carrier" refers to a diluent, adjuvant, excipient or carrier with which a compound of the invention is administered. "Preventing" or "prevention" refers to a reduction in risk of acquiring a disease or disorder (i. e., causing at least one of the clinical symptoms of the disease not to develop in a subject that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease). "Subject" includes humans. The terms "human," "patient" and "subject" are used interchangeably herein. "Therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" can vary depending on the compound, the disease and its severity, and the age, weight, etc., of the subject to be treated. "Treating" or "treatment" of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i. e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment "treating" or "treatment" refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, "treating" or "treatment" refers to modulating the disease or disorder, either physically, (e. g., stabilization of a discernible symptom), physiologically, (e. g., stabilization of a physical parameter), or both. In yet another embodiment, "treating" or "treatment" refers to delaying the onset of the disease or disorder. Mode for Invention The present invention is more specifically explained by following examples and experimental examples. However, it should be understood that the extent of the present invention is not limited to the following examples and experimental examples Example 1: 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino- benzyl)-acrylamide (Figure Removed) Step 1: Synthesis of 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid To a solution of 6-tert-butyl-pyridine-3-carboxaldehyde (1.34g, 8.75mmol) prepared by known procedure in toluene was added methyl (triphenylphosphoranylidene)acetate (2.93g), and the resulting was heated at 90°C for 3 hrs. The reaction mixture was diluted with EtOAc, and washed with water and brine. The organic layer was dried over anhydrous MgSO4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (Hex/EtOAc = 4/1) to give ester product (1.56g, 81%). The resulting ester was dissolved in 1,4-dioxane, treated with water and KOH, stirred and heated at reflux for 18hrs. The reaction mixture was cooled to room temperature, diluted with water, and then washed with ether. The aqueous phase was acidified with IN HC1, and then extracted with CHCU, and the combined organic phase was washed with brine, dried over anhydrous MgSO4 and concentrated under reduced pressure to give 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (l.00g, 68%). 1H NMR(300MHz, CDC13): δ 8.78(d, 1H, J=2.1Hz), 7.84(dd, 1H, J=2.1 and 8.4Hz), 7.78(d, lH,J=16.2Hz), 7.42(d, 1H, J=8.4Hz), 6.53(d, lH,y=16.2Hz), 1.40(s, 9H) Step 2: Synthesis of 3-(6-tert-butyl-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-benzyl)-acrylamide N-(4-Aminomethyl-2-fluoro-phenyl)-methanesulfonamide, HC1 salt (50mg, 0.20mmol) was reacted with 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (40mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-benzyl)-acrylamide (75mg, 92%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13): δ 8.70(d, 1H, J=2.1Hz), 7.77(dd, 1H, J=2.1 and 8.1Hz), 7.64(d, 1H, J=15.6Hz), 7.48(m, 1H), 7.38(d, 1H, J=8.4Hz), 7.13(m, 2H), 6.77(s, 1H), 6.51(d, lH,J=15.6Hz), 6.43(t, 1H), 4.54 (d, 2H, J=6.0Hz), 3.02(s, 3H), 1.38(s, 9H) ESI [M+Hf: 406.2. Example 2: 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-chloro-4-methanesulfonylamino- benzyl)-acrylamide (Figure Removed) N-(4-Aminomethyl-2-chloro-phenyl)-methanesulfonamide, HC1 salt (100mg, 0.35mmol) was reacted with 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (70mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(3-chloro-4-methanesulfonylamino-benzyl)-acrylamide (HOmg, 74%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13): δ 8.66(d, IH, J=2.1Hz), 7.74(dd, IH, J=2.i and S.lHz), 7.64(d, IH, J=15.6Hz), 7.57(d, IH, J=8.7Hz), 7.41(d, IH, J=2.1Hz), 7.36(d, IH, J =8.1Hz), 7.24(dd, IH, J=2.1 and 8.7Hz), 6.82(s, IH), 6.48(d, IH, J=15.6Hz), 6.42(t, IH), 4.53 (d, 2H, J=6.0Hz), 3.00(s, 3H), 1.37(s, 9H) ESI [M+H]+: 422.2. Example 3: 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Figure Removed) N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide, HC1 salt (70mg, 0.25mmol) was reacted with 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (52mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)- acrylamide (63mg, 64%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz CDC13): δ 8.71(d, IH, J =2.4Hz), 7.76(dd, IH, J=2.4 and 8.4Hz), 7.63(d, IH, J=16.0Hz), 7.39(d, IH, J=8.4Hz), 7.28(s, IH), 7.16(dd, IH, J=2.1 and ll.OHz), 6.64(s, IH), 6.52(d, IH, / =16.0Hz), 6.47(t, IH), 4.51 (d, 2H, J =6.0Hz), 3.45(s, IH), 3.24(s, 3H), 1.38(s, 9H) ESI [M+H]+: 430.1. Example 4: 3-(6-tert-Butyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-vinyl-benzyl)-acrylamide (Figure Removed) N-(4-Aminomethyl-2-vinyl-phenyl)-methanesulfonamide, HC1 salt (70mg, 0.28mmol) was reacted with 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (52mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(4-methanesulfonylamino-3-vinyl-benzyl)-acrylamide (62mg, 54%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13): δ 8.66(d, 1H, J=1.8Hz), 7.74(dd, 1H, J =2.1 and 8.4Hz), 7.63(d, lH,J=16.0Hz), 7.44(d, 1H, J=2.1Hz), 7.36(m, 2H), 7.23(m, 2H), 6.90(dd, 1H, J=11.0 and 17.0Hz), 6.70(s, 1H), 6.48(d, 1H, J=16.0Hz), 6.40(t, 1H), 5.70(d, 1H, J =17.0Hz), 5.43(d, 1H, J=11.0Hz), 4.54(d, 2H, J=5.7Hz), 2.98(s, 3H), 1.37(s, 9H) ESI [M+H]+: 414.2. Example 5: N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (Figure Removed) N-(4-Aminomethyl-2-fluoro-phenyl)-methanesulfonamide, HC1 salt(100mg, 0.40mmol) was reacted with 3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (121mg) prepared by known procedure to give N-(3-fluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)- acrylamide (118mg, 66%) after purification by column chromatography (CH2Cl2/MeOH = 20/l). 1H NMR(300MHz, CDC13 + DMSO-d6): δ 9.13(s, 1H), 8.32(t, 1H), 7.96(d, 1H, J =7.8Hz), 7.79(d, 1H, J=15.9Hz), 7.56(t, lH,J=8.4Hz), 7.38(d, lH,J=7.8Hz), 7.26(m, 2H), 6.80(d, 1H, J=15.9Hz), 4.63(d, 2H, J=5.7Hz), 3.98(m, 4H), 3.46(m, 4H), 3.13(s, 3H) ESI [M+H]+: 503.1. Example 6: N-(4-Methanesulfonylamino-3-vinyl-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-vinyl-phenyl)-rnethanesulfonamide, HC1 salt (70mg, 0.27mmol) was reacted with 3-(2-morpholin-4-yl-6-trifluoromethyl-pyridm-3-yl)-acrylic acid (81mg) to give N-(4-methanesulfonylamino-3-vinyl-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (55mg, 45%) after purification by column chromatography (CH2Cl2/MeOH - 20/1). 1H NMR(300MHz, CDC13 + DMSO-d6): δ 8.92(s, 1H), 8.18(s, 1H), 7.97(d, 1H, J =7.8Hz), 7.83(d, 1H, J=16.0Hz), 7.73(s, 1H), 7.44(m, 3H), 7.33(dd, 1H, J=11.0 and 17.0Hz), 6.83(d, 1H, J =16.0Hz), 5.93(d, 1H, J =17.0Hz), 6.55(d, 1H, J =11.0Hz), 4.69(d, 2H, J=5.1Hz), 4.01(m, 4H), 3.50(m, 4H), 3.09(s, 3H) ESI [M+Hf: 511.1. Example 7: N-(3-Chloro-4-methanesulfonylamino-benzyl)-3-(2-moq}holm-4-yl-6-trifIuoromethyl-pyridin-3-yl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-chloro-phenyl)-methanesulfonamide, HC1 salt (62mg, 0.22mmol) was reacted with 3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (67mg) to give N-(3-chloro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (93mg, 91%) after purification by column chromatography (CH2Cl2/MeOH = 20/1). 1H NMR(300MHz, CDC13 + DMSO-d6): δ 8.37(s, 1H), 8.27(t, 1H), 7.99(d, 1H, J =7.8Hz), 7.86(d, 1H, J=15.9Hz), 7.72(d, 1H, J-8.4Hz), 7.62(m, 1H), 7.44(m, 2H), 6.84(d, 1H, J=15.9Hz), 4.68(d, 2H,J=5.7Hz), 4.04(m, 4H), 3.52(m, 4H), 3.19(s, 3H) ESI[M+Hf:519.1. Example 8: N-(3-Fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-morpholin-4-yl-6-trijfluoromethyl-pyridin-3-yl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-fluoro-6-methyl-phenyl)-methanesulfonamide, HC1 salt (100mg, 0.35mmol) was reacted with 3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (116mg) to give N-(3-fluoro-4-methanesulfonylamino-5-methyl-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (120mg, 74%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13): δ 7.76(d, 1H, J=7.8Hz), 7.71(d, 1H, J=15.6Hz), 7.24(m, 3H), 6.42(d, 1H, J =15.6Hz), 6.32(s, 1H), 6.06(t, 1H), 4.59(d, 2H, J=6.3Hz), 3.85(m, 4H), 3.34(m, 4H), 3.05(s, 3H), 2.25(d, 3H, J=2.1Hz) ESI[M+H]+:517.1. Example 9: 3-(6-tert-Butyl-2-methoxy-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Formula Removed) 3-fluoro-4-methanesulfonylaminobenzylamine hydrochloride(17.8mg, 0.052mmol) was reacted with 3-(6-tert-butyl-2-methoxy-pyridin-3-yl)-acrylic acid (12mg) DMTMM(l.leq, 16mg) and NMP(1.2eq, 90µl) in THF to give the title compound (14mg, 61.8%) after purification by column chromatography (Hex/EtOAc = 3/2). 1H NMR(300MHz, CDC13): δ 7.70(d, 1H, J =15.6Hz) 7.61(d, 1H, J=9.3Hz) 7.51(m, 1H) 7.13(m, 2H) 6.90(d, 1H, J =7.8Hz) 6.84(d, 1H, J=15.6Hz) 6.61(bs, 1H) 6.10 (bs, 1H) 4.54(d, 2H, J=6Hz) 4.01(s, 3H) 3.02(s, 3H) 1.33(s, 9H) ESI [M+Hf: 436.1. Example 10: 3-(6-tert-Butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-5- vinyl-benzyl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-fluoro-6-vinyl-phenyl)-methanesulfonamide, HC1 salt (84mg, 0.30mmol) was reacted with 3-(6-tert-butyl-pyridin-3-yl)-acrylic acid (62mg) to give 3-(6-tert-butyl-pyridin-3-yl)-N-(3-fluoro-4-methanesulfonylamino-5-vinyl-benzyl)- acrylamide (34mg, 26%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13 + DMSO-d6): δ 8.68(d, 1H, J=2.4Hz), 8.09(s, 1H), 7.78(dd, 1H, J=2.1 and 8.4Hz), 7.61(s, 1H), 7.56(d, 1H, J=15.9Hz), 7.35(d, 1H, J=8.4Hz), 7.33(s, 1H), 7.12(dd, 1H, J =14.8 and IS.OHz), 7.01(dd, 1H, J =1.8 and 10.2Hz), 6.60(d, 1H, J=15.9Hz), 5.73(d, 1H, J=18.0Hz), 5.33(d. 1H, J=11.4Hz), 4.46(d, 2H, J =6.0Hz), 2.97(d, 3H, J=0.9Hz), 1.34(s, 9H) ESI [M+H]+: 432.2. Example 11: 3-(6-tert-Butyl-2-methoxy-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide, HC1 salt(82.4mg, 0.30mmol) was reacted with 3-(6-tert-butyl-2-methoxy-pyridin-3-yl)-acrylic acid (66mg), DMTMM(l.leq, 90mg) and NMP(1.2eq, 40^ ) in THF to give the title compound (51.2mg, 37.6%) after purification by column chromatography (Hex/EtOAc = 1/1). 1H NMR(300MHz, CDC13): δ 7.70(d, 1H, J=15.9Hz) 7.62(d, 1H, J=8.4Hz) 7.30(s, 1H) 7.17(m, 1H) 6.91(d, 1H, J=7.8Hz) 6.69(d, 1H, J=15.6Hz) 6.41(s, 1H) 6.02 (bs, 1H) 4.53(d, 2H, J=6Hz) 4.02(s, 3H) 3.47(s, 1H) 3 26(s, 3H) 1.34(s, 9H) ESI [M+H]+: 460.1. Example 12: N-(3-Ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide, HC1 salt (100mg, 0.22mmol) was reacted with 3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylic acid (108mg) to give N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-3-(2-morpholin-4-yl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (190mg, 100%) after purification by column chromatography (Hex/EtOAc = 1/2). 1H NMR(300MHz, CDC13 + DMSO-d6): δ 9.31(s, 1H), 8.73(t, 1H), 7.92(d, 1H, J =7.8Hz), 7.49(d, 1H, J=15.6Hz), 7.31(d, 1H, J=7.8Hz), 7.25(s, 1H), 7.18(d, 1H, J =10.8Hz), 6.71(d, 1H, J=15.6Hz), 4.38(d, 2H, J=5.7Hz), 4.14(s, 1H), 3.76(m, 4H), 3.22(m, 4H), 3.04(s, 3H) ESI [M+H]+: 527.2. Example 13: 2-(2-piperid-l-yl-6-chloro-pyridinyl-3-yloxy)-N-(3-fluoro-4- methanesulfonylamino-benzyl)-acetamide (Formula Removed) N-(4-Aminomethyl-3-fluoro-phenyl)-methanesulfonamide HC1 salt (32 mg, 0.12 mmol) and NMP (0.05 ml) were added in 20 ml of THF. The mixture was stirred for 10 mins. DMTMM (51 mg, 0.18 mmol) and 2-(2-piperid-l-yl-6-chloro-pyridin-3-yloxy)-acetic acid (20 mg, 0.092 mmol) were added into the mixture. The reaction mixture was stirred overnight. The reaction solvent was removed in vacuo. The residue was extracted with ethylacetate (30 ml x 3) and H2O (30 ml). A combined organic layer was washed with sat. NaHCO3 (30ml), and with brine (30 ml), dried with MgSO4, and concentrated in vacuo. The residue was purified with column chromatography to yield a white solid (11 mg). 1H NMR (CDC13, 300 MHz) δ 7.87 (d, J = 15.9 Hz, 1H), 7.62 (d, J = 9.0 Hz, 1H), 7.51 (t, j = 7.8 Hz, 1H), 7.12 (m, 2H), 6.39 (br, 1H), 6.51 (d, J = 9.0 Hz, 1H), 6.20 (d, J = 15.6 Hz), 6.00 (br, 1H), 5.53 (d, J = 6.3 Hz, 2H), 3.60 (m, 4H), 3.01 (s, 3H), 1.65 (m, 6H) ESI [M+H]+: 467.1. Example 14: 3-(6-Chloro-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Formula Removed) Step 1: 3-(6-Chloro-pyridin-3-yl)-acrylic acid methyl ester To 6-chloro-pyridine-3-carboxaldehyde (300 mg, 2.12 mmol) in toluene was added methyl(triphenylphosphoranylidene)acetate (708 mg, 2.12 mmol) and the solution was refluxed for 6 hrs. The reaction mixture was diluted with EtOAc and then washed three times with H2O, brine, dried. Na2SO4, filtered and concentrated under reduced pressure. The obtained residue was column-chromatographed to yield 3-(6-chloro-pyridin-3-yl)- acrylic acid methyl ester (380 mg, 90 %). 1H NMR (300 MHz, CDC13): δ 8.51 (d, 1H, J= 2.7 Hz), 7.80 (dd, 1H, J = 8.1, 2.4 Hz), 7.65 (d, 1H, J = 15.9 Hz), 7.36 (d, 1H, J= 8.4 Hz), 6.48 (d, 1H, J= 15.9 Hz), 3.83 (s, 3H). Step 2: 3-(6-Chloro-pyridin-3-yl)-acrylic acid 3-(6-Chloro-pyridin-3-yl)-acrylic acid methyl ester (107 mg, 0.541 mmol) in THF was added to a solution of 0.5 N-LiOH (2 eq) and the mixture was stirred for 3 hrs at room temperature. The resulting residue was dissolved in HaO and then washed three times with Et2O, neutralized with IN HC1 to pH 5-7. The resulting solid filtered and washed with H2O and then dried in vacuo to give 3-(6-chloro-pyridin-3-yl)-acrylic acid (80 mg, 80 %). 1H NMR (300 MHz, DMSO-d6): δ 8.64 (s, 1H), 8.16 (d, 1H, J = 8.1 Hz), 7.54 (d, 1H, J= 16.8 Hz), 7.50 (d, 1H, J= 9.9 Hz), 6.63 (d, 1H, J= 15.9 Hz). Step 3: 3-(6-Chloro-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide HC1 salt (78.3 mg, 0.272 mmol) was suspended in THF and treated with triethylamine (30 mg, 0.299 mmol) and then the resulting mixture was stirred for lOmins. 3-(6-chloro-pyridin-3-yl)-acrylic acid (50 mg, 0.272 mmol) was added to the reaction mixture followed by DMTMM (82 mg, 0.299 mmol) after 10 mins. The resulting mixture was stirred overnight at ambient temperature and then diluted with EtOAc. The resulting solution was washed successively with water, sat'd NaHCO3 (x2), brine, and then dried over anhyd. NasSO^ filtered and concentrated under reduced pressure. The crude residue was recrystallized (CH2Cl2) to yield the title compound (26 mg, 23 %). 1H NMR (300 MHz, DMSO-d6): d 9.54 (s, 1H), 8.74 (t, 1H, J = 6.0 Hz), 8.61 (d, 1H, J = 2.4 Hz), 8.07 (dd, 1H, J= 8.4, 2.4 Hz), 7.56 (d, 1H, J = 8.4 Hz), 7.51 (d, 1H, J= 15.9 Hz), 7.34 (t, 1H, J= 8.1 Hz), 7.19 (d, 1H, J = 12.0 Hz), 7.12 (d, 1H, J= 8.4 Hz), 6.79 (d, 1H, J= 15.9 Hz), 4.39 (d, 2H, J= 5.7 Hz), 3.00 (s, 3H). ESI [M+H]+; 408.0. Example 15: 3-(6-Bromo-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Formula Removed) Step 1: 3-(6-Bromo-pyridin-3-yl)-acrylic acid methyl ester To 6-bromo-pyridine-3-carboxaldehyde (300 mg, 1.61 mmol) in toluene was added methyl(triphenylphosphoranylidene)acetate (647 mg, 1.94 mmol) and the solution was refluxed for 6 hrs. The reaction mixture was diluted with EtOAc and then washed three times with H2O, brine, dried. Na2SO4, filtered and concentrated under reduced pressure. The obtained residue was column-chromatographed to yield 3-(6-bromo-pyridin-3-yl)-acrylic acid methyl ester (380 mg, 97 %). 1H NMR (300 MHz, CDC13): δ 8.47 (d, 1H, J = 2.4 Hz), 7.68 (dd, 1H, J= 8.4, 2.4 Hz), 7.60 (d, 1H, J= 15.9 Hz), 7.51 (d, 1H, J= 8.4 Hz), 6.49 (d, 1H, J= 15.9 Hz), 3.81 (s, 3H). Step 2: 3-(6-Bromo-pyridin-3-yl)-acrylic acid To 3-(6-bromo-pyridin-3-yl)-acrylic acid methyl ester (120 mg, 0.495 mmol) in THF was added a solution of 0.5 N-LiOH (2 eq) and the mixture was stirred for 3 hrs at room temperature. The resulting residue was dissolved in H2O, then washed three times with EtjO, and neutralized with IN HC1 to pH 5-7. The resulting solid filtered and washed with H2O and then dried in vacuo to give 3-(6-bromo-pyridin-3-yl)-acrylic acid(100mg, 88%). 1H NMR (300 MHz, DMSO-d6): δ 8.67 (d, 1H, J = 2.1 Hz), 8.11 (dd, 1H, J= 8.4, 2.1 Hz), 7.69 (d, 1H, J = 8.4 Hz), 7.59 (d, 1H, J= 15.9 Hz), 6.71 (d, 1H, J= 15.9 Hz). Step 3: 3-(6-Bromo-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4-methanesulfonylamino-benzyl)-acrylamide N-(4-Ammomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonamide HC1 salt (63 mg, 0.219 mmol) was suspended in THF and treated with triethylamine (25 mg, 0.241 mmol) and then the resulting mixture was stirred for lOmins. 3-(6-bromo-pyridin-3-yl)-acrylic acid (50 mg, 0.219 mmol) was added to the reaction mixture followed by DMTMM (66 mg, 0.241 mmol) after 10 mins. The resulting mixture was stirred overnight at ambient temperature and then diluted with EtOAc. The resulting solution was washed successively with water, sat'd NaHCO3 (x2), and brine, and then dried over anhyd. Na2SO4, filtered and concentrated under reduced pressure. The crude residue was recrystallized (EtOAc/n-Hexane) to yield the title compound (71 mg, 72 %). 1H NMR (300 MHz, DMSO-d6): δ 9.42 (s, 1H), 8.77 (t, 1H, J= 6.0 Hz), 8.60 (d, 1H, J= 2.4 Hz), 7.96 (dd, 1H, J = 8.1, 1.8 Hz), 7.70 (d, 1H, J= 8.1 Hz), 7.48 (d, 1H, J = 15.9 Hz), 7.28 (s, 1H), 7.27 (d, 1H, J= 8.7 Hz), 6.81 (d, 1H, J= 15.9 Hz), 4.50 (s, 1H), 4.39 (d, 2H, J= 5.7 Hz). 3.06 (s, 3H). ESI [M+H]+; 452.0. Example 16:3 -(6-Chloro-pyridin-3 -yl)-N-(3 -fluoro-4-methanesulfonylamino-benzyl)- acrylamide (Formula Removed) 3-Fluoro-4-mcthanesulfonylaminobenzylamine hydrochloride (51 mg, 0.201 tnmol) was suspended in THF and treated with triethylamine (23 mg, 0.22 mmol) and then the resulting mixture was stirred for lOmins. 3-(6-chloro-pyridin-3-yl)-acrylic acid (37 mg, 0.201 mmol) was added to the reaction mixture followed by DMTMM (61 mg, 0.22 mmol) after 10 mins. The resulting mixture was stirred overnight at ambient temperature and then diluted with EtOAc. The resulting solution was washed successively with water, sat'd NaHCO3 (x2), brine, and then dried over anhyd. Na2SO4, filtered and concentrated under reduced pressure. The crude residue was column-chromatographed to yield the title compound (74 mg, 96 %). 1H NMR (300 MHz, DMSO-d6): δ 9.54 (s, 1H), 8.74 (t, 1H, J= 6.0 Hz), 8.62 (d, 1H, ' J= 2.4 Hz), 8.07 (dd, 1H, J= 6.0, 2.4 Hz), 7.57 (d, 1H, J= 8.4 Hz), 7.51 (d, 1H, J = 15.9 Hz), 7.34 (t, 1H, J= 8.1 Hz), 7.19 (d, 1H, J= 12.0 Hz), 7.12 (d, 1H, J = 8.4 Hz), 6.79 (d, 1H, J= 15.9 Hz), 4.39 (d, 2H, J= 5.7 Hz), 3.00 (s, 3H). ESI [M+H]+; 384.0. Example 17: 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Formula Removed) 3-Fluoro-4-methanesulfonylaminobenzylamine hydrochloride (41.2mg, 0.162mmol) was reacted with 3-(6-tert-butyl-4-trifluoromethyl-pyridin-3-yl)-acrylic acid (l.Oeq, 44.2mg) DMTMM(1.0cq, 44.8mg) and NMP(1.2eq, 22ul) in THF to give the title compound (48mg, 62.6%) after purification by column chromatography (Hex/EtOAc = 1/1). 1H NMR(300MHz, CDC13): δ 8.84(s, 1H) 7.93(d, 1H, J=15.3Hz) 7.57(s. 1H) 7.52(t, 1H) 7.14(m, 1H) 6.60(bs, 1H) 6.45(d, 1H, J=15.6Hz) 6.24(bs, 1H) 6.50(bs, 1H) 4.54(d, 2H, y=6.0Hz) 3.03(s, 3H) 1.39(s, 9H) ESI [M+H]+: 474.2. Example 18: 3-(6-tert-Butyl-4-trifluoromethyl-pyridin-3-yl)-N-(3-ethynyl-5-fluoro-4- methanesulfonylamino-benzyl)-acrylamide (Formula Removed) N-(4-Aminomethyl-2-ethynyl-6-fluoro-phenyl)-methanesulfonaniide HC1 salt (11.2mg, 0.04mniol) was reacted with 3-(6-tert-butyl-4-trifluoromethyl-pyridin-3-yl)-acrylic acid (l.Oeq, ll.Omg) DMTMM(1.0eq, ll.lmg) and NMP(1.2eq, 6ul) in THF to give the title compound (6mg, 30.2%) after purification by column chromatography (Hex/EtOAc = 3/2). 1H NMR(300MHz, CDC13): δ 8.85(s, 1H) 7.95(d, 1H, J=13.5Hz) 7.58(s, 1H) 7.32(bs, 1H) 7.20(d, 1H, J=12.6Hz) 6.05(bs, 1H) 4.54(d, 1H, J=6.0Hz) 3.49(s, 1H) 3.27(s, 3H) 1.40(s, 9H) ESI [M+H]+: 498.2 Example 19: N-(3 -Fluoro-4-methanesulfony lamino-benzy l)-3 -(6-piperid-1 -y 1- pyridinyl-3-yl)-acrylamide (Formula Removed) Step 1: 3-(6-piperid-l-yl-pyridinyl-3-yl)-acrylic acid methyl ester 3-(6-Bromo-pyridin-3-yl)-acrylic acid methyl ester (180 mg, 0.74 mmol) was added to piperidine (1 ml) and the mixture was stirred for 1.5 hrs at room temperature. The reaction mixture was diluted with EtOAc and then washed three times with H2O, brine, dried. Na2SO4, filtered and concentrated under reduced pressure. The obtained residue was column-chromatographed to yield 3 -(6-piperid- l-yl-pyridinyl-3-yl)-acrylic acid methyl ester (60 mg, 33 %). 1H NMR (300 MHz, CDC13): δ 8.25 (d, 1H, J= 2.1 Hz), 7.63 (dd, 1H, J = 6.0, 2.4 Hz), 7.58 (d, 1H, J= 15.9 Hz), 6.62 (d, 1H, J= 9.3 Hz), 6.21 (d, 1H, J = 15.9 Hz), 3.78 (s, 3H), 3.64-3.61 (m, 4H), 1.66 - 1.60 (m, 6H). Step 2: N-(3-Fluoro-4-methanesulfonylamino-benzyl)-3 -(6-piperid-1 -yl-pyridinyl-3-yl)-acrylamide 3-Fluoro-4-methanesulfonylaminobenzylamine hydrochloride (25.2 mg, 0.099 mmol) was suspended in THF and treated with triethylamine (11 mg, 0.108 mmol) and then the resulting mixture was stirred for lOmins. 3-(6-piperid-1-yl-pyridinyl-3-yl)-acrylic acid (23 mg, 0.099 mmol) was added to the reaction mixture followed by DMTMM (30 mg, 0.108 mmol) after 10 mins. The resulting mixture was stirred overnight at ambient temperature and then diluted with EtOAc. The resulting solution was washed successively with water, sat'd NaHCO3 (x2), brine, and then dried over anhyd. Na2SO4, filtered and concentrated under reduced pressure. The crude residue was recrystallized (CH2Cl2) to yield the title compound (15 mg, 35 %). 1H NMR (300 MHz, CDC13): δ 8.25 (d, 1H, J= 2.7 Hz), 7.59